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ABSTRACT 
 
ELECTROCHEMICALLY MODULATED GENERATION/DELIVERY OF NITRIC 
OXIDE (NO) FROM NITRITE FOR BIOMEDICAL APPLICATIONS 
by 
Hang Ren 
 
Chair: Mark E. Meyerhoff 
 
In this dissertation research, the development of a new electrochemically 
modulated NO generation/delivery approach was examined.  Further, the potential 
application of this approach in devising advanced thromboresistant/bactericidal 
intravascular catheters and a new NO inhalation therapy system was explored. 
Nitric oxide can be generated from nitrite via two electrochemical approaches: 1) 
using a Cu0 wire and an applied anodic/cathodic potential pulse sequence to 
electrochemically reduce nitrite to NO (Chapter 2); and 2) using Pt/Au or other working 
electrodes and a soluble Cu(II)-ligand complex as mediator to reduce nitrite to NO (Chapter 
3).  The temporal pattern of NO generation can be precisely modulated in the latter system 
by the applied potential or current.  This electrochemical NO release system was first 
incorporated within intravascular catheters, which exhibited much reduced clotting (~85 %) 
 xxv 
 
in vivo and significantly less (>99.9%) microbial biofilm in vitro compared to non-NO 
release control devices.  Further, this NO release concept was combined with an 
amperometric oxygen sensor (PO2 sensor) within a dual-lumen catheter configuration 
(Chapter 4) for intravascular continuous monitoring of PO2 levels.  Electrochemical NO 
release was fully compatible with PO2 sensing and yielded more accurate PO2 
measurements (vs. controls) when implanted in arteries of pigs for 20 h.  In Chapter 5, the 
electrochemical NO release catheters were used for controlled delivery of NO to elucidate 
the dosage effect of NO on mature P. aeruginosa biofilm.  Fluxes of NO >0.5 × 10-10 mol 
min-1 cm-2 showed 99% killing of the biofilm in 3 h, and such an effect was in synergy with 
added gentamicin.  In Chapter 6, the new electrochemical NO delivery method was 
employed for developing a gas phase NO inhalation (INO) system.  Relatively pure gas 
phase NO in the range of 1–150 ppmv can be created by this system.  Finally, the 
partitioning and diffusion properties of NO within several biomedical polymers was 
examined (Chapter 7), with silicone rubber exhibiting the optimal transport of NO.   
Overall, electrochemical delivery of NO provides both a tool for fundamental 
biological studies, as well as a means to improve the biocompatibility of medical devices. 
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CHAPTER 1.  
 
 
INTRODUCTION 
 
1.1 Challenges for Implantable Medical Devices 
1.1.1 Risk of Infection 
Implanted medical devices are frequently used in hospitals for therapeutic and 
diagnostic purposes.  There is a wide variety of such devices ranging from central venous 
catheters for infusion and blood draw, to implanted artificial heart valves for valvular heart 
disease, and to urinary catheters to facilitate urine drainage.  These devices are designed to 
facilitate diagnosis and treatment and to improve the quality of health care.  However, the 
use of many of these medical devices, especially the invasive ones, are often associated 
with increased risk of infection.  Indeed, three device-associated infections – catheter-
associated bloodstream infection (CABSI), catheter-associated urinary tract infection 
(CAUTI) and ventilator-associated pneumonia (VAP), have been listed among the four 
major healthcare-associated infections (HAI) by Centers for Disease Control and 
Prevention (CDC). 1  An estimated 250,000 CABSIs occur each year in the US alone, 
leading to prolonged hospital stays, substantially increased medical costs ($2.3 billion per 
year), and as many as 28,000 deaths.1,2  On the other hand, CAUTIs contribute to 0.5-0.7 
million nosocomial infections,3 with a cumulative incidence of 3-6% per day of 
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catheterizations (50% at 10 days, >90% at 28 days, 100% long term)4 leading to 
complications, and approximately ten thousand deaths annually.5   
These infections are caused by invasion of pathogenic microbes.  For example,  
coagulase-negative staphylococci (CoNS), Staphylococcus aureus, enterococci, and 
Candida species account for ~70% of CABSIs,6,7 while Escherichia coli, Candida species, 
Enterococcus species and Pseudomonas aeruginosa account for >60% of CAUTIs.8  One 
challenge for treating such infections is the formation of biofilms by these pathogenic 
microbes.  Biofilms are groups of sessile cells embedded in a self-produced extracellular 
polymeric substance (EPS) matrix that are attached to a surface (e.g., catheter surface, etc.).  
Formation of biofilms starts with the attachment of planktonic cells to surfaces, followed 
by development via cell growth/colonization, maturation by formation of EPS, and finally 
dispersal to start of a new cycle (Figure 1.1).  Once formed, biofilms are usually associated 
with significantly increased antibiotic-resistance and are therefore notoriously hard to cure.  
Unfortunately, 80% of all nosocomial bacterial infections are associated with the formation 
of biofilms.9  In the case of a catheter, the biofilms formed are so resistant that they are 
virtually impossible to eradicate unless the whole device is physically removed.10 
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Figure 1.1. Development of bacterial biofilms on surfaces. 
 
1.1.2 Risk of Clotting 
Another challenge with medical devices that are in contact with flowing blood is 
thrombosis, or clotting.  Once a device is in contact with blood, a foreign surface induced 
coagulation cascade can be triggered.  The cascade starts with adsorption of proteins in the 
blood in seconds, including von Willebrand factor (vWF), fibrinogen, fibronectin, and 
vitronectin.  This is followed by platelet adhesion and activation, and amplification 
reactions with the formation of thrombin and fibrin, and finally the formation of a mature 
clot within hours (see Figure 1.2).11  
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Figure 1.2. Sequence of events that lead to the formation of thrombus induced by a foreign surface. 
 
Such foreign surface induced clotting has a severe impact on the functions of many 
medical devices, including bloodstream catheters, dialysis catheters, oxygenators, artificial 
heart valves, and implantable sensors.  For example, the formation of a clot on the tip of a 
bloodstream catheter often impedes/prevents blood draw or infusion of drugs/nutrients.  
Consequently, the dysfunctional catheter has to be surgically removed and replaced.  
Another such example involves intravascular chemical sensors that could potentially 
measure blood gases, pH, electrolytes, glucose, lactate and other chemicals continuously 
in the blood.  The clots formed on the surface of the sensors can isolate the sensors from 
the analytes in the blood, yielding inaccurate/unreliable results.  More importantly, foreign 
surface induced clotting/thrombosis can often pose severe medical complications to the 
patients, leading to clots that can potentially dislodge, which significantly increases the risk 
of stroke, heart attack, and other life-threatening complications.12  
It should be noted that although usually treated separately as different challenges 
(from a therapeutic/drug standpoint), thrombosis and infection are actually closely linked.  
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Bacteria can induce clot formation both directly and indirectly.  Pathogenic bacteria such 
as S. aureus can secrete crucial factors including coagulase and von Willebrand factor 
binding protein (vWbp), which promote clotting.13  Recently, it has also been shown that 
bacteria, including Bacillus cereus and Bacillus anthracis, can cluster and directly initiate 
blood clot formation.14  This suggests that when addressing the overall issue of thrombosis, 
infection induced clotting should also be taken into account.  It is, therefore, desirable to 
develop new strategies that can contend with both the risks of infection and thrombosis 
simultaneously.  
 
1.2 Current Strategies/Efforts 
1.1.1 Anti-Infection Strategies 
Currently, the prevention of device-associated infections focuses on different 
aspects from standardization of clinical practices (e.g., handling of the devices, sterilization, 
etc.) to improvement/intervention in the devices themselves.  Clinical practice guidelines 
for preventing HAIs have been drafted by the CDC, instructing clinical practitioners to 
comply with hygiene recommendations and emphasizing the disinfection of the devices.15  
However, device-associated infections still occur frequently.  Treatment of such infections 
relies heavily on prolonged exposure to high-dose antibiotics.16  However, the dose of such 
antibiotics are sometimes inappropriate and can induce antibiotic resistance.17  Moreover, 
traditional antibiotics are designed to eradicate planktonic bacteria, but, as stated earlier, 
many infections are associated with bacterial biofilms, which are not effectively targeted 
by traditional antibiotics. 
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To fight infections more effectively, many different strategies involving 
modification of medical devices themselves have been proposed.  Most of these can be 
classified into two categories: passive surface modification and active chemical release.  
Passive surface modification refers to changing the physiochemical properties of the 
surfaces to prevent the attachment of bacteria to the surface, or to kill the bacteria near the 
surface.  To this end, surfaces have been modified by attaching polyethylene glycol 
(PEG),18 poly(ethylene oxide) brushes,19 hydrophilic polyurethane,20 side chains with 
negative charges,21 poly-cations (especially quaternary ammonium salts),22 and 
antimicrobial peptides.23  Surfaces have also been patterned with arrays of submicron-
/nano-structure,24-26 and infused with a fluorinated oil liquid to lower the surface energy 
for initial attachment.27  However, the effectiveness of these modifications varies widely 
between different bacterial species.  Furthermore, a conditioning film (e.g., protein) often 
forms on the surface under physiological conditions and can change or mask the surface 
properties provided by these different surface modification strategies.  
The second class of strategies – the active release strategies – are based on the 
release of antimicrobial agents from the surface of the devices to inhibit/kill the bacteria 
from initial adhesion, or to disturb the formation of biofilms.28  Antimicrobial impregnated 
catheters have been developed and clinically used, but dosage is hard to control as 
susceptibility varies with different bacterial species.29  Inappropriate dosage could promote 
antibiotic resistance, or even the formation of biofilms.30  In clinical studies, reduction of 
CAUTIs via the use of antimicrobial-impregnated catheters was not regarded as clinically 
useful.31  Silver-alloy particles have also been applied as coatings for urinary catheters.32  
However, these coatings have proved clinically ineffective in reducing the incidence of 
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CAUTIs.31  Release of antibodies33 and quorum sensing inhibitors34,35 have also been 
proposed, either to prevent biofilm formation or to disperse existing biofilms.  
Despite all these efforts, the problem of device-induced infections has yet to be 
solved.  Neither has the toxicity of some strategies against human cells/tissues been 
addressed.  The development of new, more powerful techniques to prevent/reduce biofilms 
while being benign to healthy human cells or tissues is therefore of utmost importance. 
1.1.2 Anti-Clotting Strategies 
To address the problem of clotting/thrombosis, heparin, a highly sulfated 
glycosaminoglycan polymer with a very high negative charge density, has been routinely 
used.  For example, dilute heparin solution has been intermittently or continuously injected 
into vascular catheters as a lock solution.  However, the usage of heparin poses the risk of 
systemic anticoagulation (especially with inadvertent overdose).  Moreover, heparin 
induced thrombocytopenia (HIT)36 and heparin sensitivity/resistance is also a concern.37  
More importantly, heparin, acts as an anticoagulant by inactivating thrombin and factor Xa 
through an antithrombin-dependent mechanism38 and therefore it does not address the 
primary event in the foreign surface induced thrombosis process; that is platelet 
activation/adhesion and aggregation. 
Strategies to modify device surfaces have also been attempted, including using ultra 
smooth silicone rubber39 or polyurethane,40 immobilizing poly(ethylene oxide),41 pre-
exposure to albumin42 or other coating proteins,43 and binding of heparin in an ionic 44 or 
covalent fashion.45  Surface patterning/texturing,46 as well as infusion with non-stick liquid  
has also been pursued.47  Unfortunately, these approaches have not solved the clotting 
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problem completely.  On the other hand, as stated in Section 1.1.2, clotting can also be 
induced by bacterial infection and the problem of infection and clotting should really be 
considered jointly.  
 
1.3 Nitric Oxide to the Rescue 
1.1.3 Background/Properties of Nitric Oxide 
To combat infection and clotting for medical devices, the use of nitric oxide (NO), 
a natural molecule in the human body, has been proposed.48-50  Nitric oxide is a diatomic 
gas radical molecule that is involved in many different physiological processes, including 
vasodilation,51 anti-clotting,52 antimicrobial,53 neuron transmission,54 and wound healing,55 
just to name a few.  In the body, NO is produced by a two-step oxidation of L-arginine to 
citrulline and NO via the enzyme nitric oxide synthase (NOS) (Figure 1.3).  Three types of 
NOS isozymes have been discovered, including iNOS (inducible NOS), eNOS (endothelial 
NOS) and nNOS (neuronal NOS), and their activities are associated immune response, 
vascular functions and neuron transmission, respectively.56  The healthy endothelium cells 
secrete NO through eNOS at fluxes from (0.5–4.0) × 10-10 mol cm-2 min-1 (0.5–4.0 flux 
unit) and the NO emitted acts as a powerful anti-clotting and anti-thrombotic agent at the 
interface of the endothelial cells and flowing blood.57  The mechanisms by which NO is 
able to temporarily inhibit or anesthetize platelets are both direct and indirect.58  In the 
blood, NO has a short lifetime (< 1 s),59 and the excess NO is scavenged immediately by 
oxyhemoglobin (OxyHb) in red blood cells to form non-toxic nitrate.60  Consequently, 
those platelets in circulating blood exposed to the endothelium are inhibited temporarily, 
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while those distant from the surface remain functional.  It is precisely this close proximity 
effect and short lifetime of NO (no systemic effects) that makes the use of NO release very 
attractive for biomedical applications, since the therapeutic process will mimic what occurs 
physiologically at the endothelium surface.  
 
 
Figure 1.3. NO production from a two-step oxidation L-arginine via nitric oxide synthase (NOS).  
  
Nitric oxide is also recognized as a potent endogenous antimicrobial and antifungal 
agent.61  In fact, nasal epithelial cells are known to produce NO at high levels to prevent 
airway infection.62  Nitric oxide and peroxynitrite (ONOO-), formed by phagocytes 
undergoing simultaneous oxidative burst, have been shown to be bactericidal against 
numerous pathogens.63  Furthermore, NO has also been shown to act as a signaling 
molecule for the dispersal of biofilms.64  The combination of the killing and dispersal 
effects of NO towards bacteria and their biofilms suggests that NO can be an excellent 
candidate species to combat medical device induced infections. 
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1.1.4  Previous Research on NO Release from Polymeric Materials 
Since NO is a gas molecule and has a relatively short lifetime in blood, appropriate 
delivery methods/mechanisms are necessary for its application, especially in medical 
devices.  Specifically, NO needs to be delivered to the place where it is needed, e.g. at the 
surface of a given medical device, before it is consumed/scavenged by red cell hemoglobin.  
To this end, many different classes of NO donors have been developed, including organic 
nitrates, organic nitrites, metal-NO complexes, diazeniumdiolates, S-nitrosothiols, etc.65,66  
Among these, diazeniumdiolates and S-nitrosothiols have been extensively investigated in 
the development of NO releasing polymers, particularly because of their appropriate 
release mechanism. 
Diazeniumdiolates are formed by the reaction of secondary amines with NO under 
high pressure.  In the presence of protons, diazeniumdiolates can decompose and release 
NO according to Reaction 1.1.  This is the major NO release mechanism for 
diazeniumdiolates, although thermal decomposition also occurs slowly at room 
temperature.67  Different diazeniumdiolates have been synthesized and their half-lives 
range from seconds to days in phosphate buffered saline (PBS).68,69  To better enhance their 
lifetime as well as to apply them into medical devices, diazeniumdiolates have been 
blended into,49 as well as covalently attached to different biopolymers including 
polyurethanes70 and silicone rubber.71  When these diazeniumdiolates containing polymers 
are in contact with blood/water, the protons in the blood/water can trigger the NO release 
(Figure 1.4).  Lipophilic diazeniumdiolates have also been prepared to slow the leaching 
of these donors from the polymers.72  
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  (Reaction 1.1) 
 
 
Figure 1.4.  Schematics of NO release from a diazeniumdiolate blended polymer. 
 
The second class of NO donors that have been investigated to prepare NO releasing 
biomedical polymers is S-nitrosothiols (RSNOs).  S-nitrosothiols are naturally present in 
the human body and S-nitroso-human serum albumin and S-nitrosoglutathione are the two 
major forms in blood.73  These endogenous RSNOs are thought to serve as 
reservoirs/carriers for NO, as NO itself has a limited diffusion range in blood.74  The 
RSNOs can decompose and release NO via several different mechanisms, as shown in 
Reaction 1.2, including heat, light or catalytic species (e.g., copper(I/II), organo-
selenium).75  To develop NO releasing polymers, S-nitrosothiols have also been 
blended76,77 or impregnated78 into polymers, as well as covalently attached to the polymer 
backbones79 and polymer fillers such as silica particle.80  The release of NO can be 
triggered by the expedited decomposition of RSNOs at body temperature (37 °C).  
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Temporal and spatial control of NO release by an external light source has also been 
demonstrated.80 
  (Reaction 1.2)  
Although these NO donor incorporated polymers have been shown to exhibit much 
improved anti-clotting/antimicrobial properties, none have yet been used in clinical 
settings.  Several issues have limited their commercialization.  First, most 
diazeniumdiolates and RSNOs containing polymers are unstable at body temperature or in 
buffer—that is how NO release is usually triggered.  Such instability actually resides in the 
basic chemistry of these NO donors—the diazeniumdiolate are moisture and heat sensitive, 
whereas the RSNOs are light and heat sensitive, which increases the costs for storage and 
shipping of such NO releasing polymers.  Secondly, leaching of the donors and their 
degradation products hinder their potential clinical application, until it can be clearly shown 
that these products are non-toxic.  The leaching process not only significantly reduces the 
duration of NO release, but also poses potential health risks to the hosts, especially for 
diazeniumdiolates, which can back-react with NO oxidation products to form carcinogenic 
nitrosamines.48   
A strategy based on NO generation from endogenous RSNOs has also been 
attempted.  Instead of incorporating NO donors, the polymers are simply coated with 
RSNO decomposition catalysts, such as lipophilic copper(II) complexes and 
organoselenium species.81-84  Once in contact with blood, the endogenous RSNOs in the 
blood can decompose catalytically and release NO at the polymer surfaces.  However, the 
endogenous RSNOs exist in limited amounts in the body, and the level of these can vary 
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greatly from one individual to another, which creates challenges for the application of this 
type of NO generation strategy.85 
1.1.5  Electrochemically Modulated NO Release Method 
Most of the above mentioned NO release strategies, except for the photo-initiated 
NO release from RSNOs, are passive and uncontrolled.  Once triggered (sometimes even 
simply by storing in buffer), the NO release cannot be paused, and this might waste a 
significant amount of the NO donor capability before the device is ever implanted into a 
patient.  In contrast, modulated release can save the NO donors by releasing NO only when 
needed, or boost the therapeutic effect by easily switching to higher flux of NO release.  In 
addition, fast temporal control of precise NO fluxes enabled by such a modulated release 
strategy can greatly facilitate fundamental studies where the effect of a precise and steady 
release of NO needs to be defined. 
To better control the release of NO, new strategies using electrochemical methods 
have been proposed, and electrochemical NO generation from diazeniumdiolates and 
RSNOs has been attempted.86-88  For the diazeniumdiolate systems, protons generated 
locally at the surface of an electrode by electrochemical water oxidation can occur, which 
triggers the NO release from diazeniumdiolate in the solution.89  Efforts have also been 
attempted to generate NO from direct electrochemical reduction of RSNOs.86  However, 
both diazeniumdiolates and RSNOs are generally unstable in solution.  Another drawback 
of these systems is that the product composition is usually complex, especially for 
reduction of RSNOs.86 
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In contrast to diazeniumdiolates and RSNOs, inorganic nitrates and nitrites are 
relatively stable in solution and cost-effective.  To investigate the possibility of NO 
generation from inorganic nitrates and nitrites, thermodynamic data of nitrogen species are 
summarized in an oxidation state diagram (Frost diagram) in Figure 1.5.90  The y-axis of 
the Frost diagram (nE) is the standard redox potential of the reaction from nitrogen species 
to N2, times the number of electrons transferred, which is proportional to the Gibbs free 
energy.  It can be seen that reduction of both nitrate and nitrite to NO is thermodynamically 
downhill, although N2 and ammonia are the most stable forms under standard conditions.  
However, this diagram is based on thermodynamics and therefore shows no kinetic 
information.  Indeed, the reduction of nitrate and nitrite are generally kinetically controlled 
and usually requires an overpotential to occur on most inert electrodes (e.g., platinum91).  
Yet another challenge for NO generation from nitrite or nitrate is the selectivity.  Indeed, 
it may be difficult to control the electrochemical reduction of nitrite or nitrate to yield only 
NO, as the product composition is usually complex with different reduced nitrogen species 
being formed (including N2O).
91  Catalysts are therefore generally required to improve the 
turnover numbers as well as the selectivity for these reduction reactions.  Although 
development of a selective and robust catalyst for NO generation can be challenging, in 
nature, bacteria can selectively and efficiently perform the nitrate reduction and nitrite 
reduction enzymatically in the denitrification pathway using nitrate reductase and nitrite 
reductase, respectively.92  
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Figure 1.5. Frost diagram of nitrogen species in acidic (blue) and basic (black) solutions. 
 
To generate NO from nitrate and nitrite in aqueous solution by electrochemical 
methods, a few systems have been suggested.  One involves NO generation from the 
reaction between nitric acid with Cu0 formed by electrochemical reduction of Cu(II).93  
Another example utilizes iron meso-tetrakis (4-N-methylpyridiniumyl) porphyrin 
([FeIII(TMPyP)]5+) to generate NO from nitrite in a flow cell.94  The first step involves the 
electrochemical reduction of [FeIII(TMPyP)]5+and nitrite to [FeII(NO2
-)2(TMPyP)]
2+ and 
[FeII(NO)(TMPyP)]4+ sequentially.  In the second step, the newly formed 
[FeII(NO)(TMPyP)]4+ is further electrochemically oxidized back to ([FeIII(TMPyP)]5+to 
complete the catalytic cycle (see the diagram of the mechanism in Figure 1.6).  
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Figure 1.6. Mechanism of electrochemical generation of NO from nitrite and an iron porphyrin 
catalyst in aqueous solution. (Reprinted from Chi et. al. Inorg. Chem. 2004, 43, 8437.) 94 
 
 
Figure 1.7. Schematic of the electrochemical NO generating catheter configuration.  A copper wire 
serves as the working electrode and silver/silver chloride wire serves as the reference electrode.  
PTFE coating prevents the two wires from short-circuit.  The inner filling solution contains NaNO2, 
NaCl, EDTA, Na2HPO4, NaH2PO4, pH 6.8. 95 
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In our lab, Hofler et al.95 pioneered an electrochemical NO releasing method from 
inorganic nitrite and a Cu0 electrode.  A copper wire (working electrode), and silver/silver 
chloride wire (reference and counter electrode), were sealed inside a silicone tubing filled 
with concentrated nitrite solution (see Figure 1.7 for the schematic).  Electrochemical 
potential pulses, with potentials periodically oscillating between anodic and cathodic, were 
used to generate NO.  The anodic pulses generate Cu(I) species which reduce nitrite to NO.  
Cathodic pulses reduce/clean the passivating mixed copper oxide and hydroxide layer 
formed during the anodic pulses.  By continually repeating the electrochemical pulse cycles, 
NO can be continuously generated, which then diffuses through the silicone rubber wall of 
the catheter.  The NO flux can be turned “on” and “off” on demand (Figure 1.8).  A catheter 
incorporating such electrochemical NO release reduced biofilm formation on the catheter 
surface, which demonstrated the potential of the electrochemical NO release method in 
antibiofilm application.  However, the highest flux of NO released from these catheters is 
~0.6 flux units, which is at the lower end of the physiological range; therefore, their 
antithrombogenic application in vivo has not yet been demonstrated.  In addition, the pulse 
cycles in this system requires relatively more complex circuits.  
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Figure 1.8. Electromodulated NO generation in silicone rubber catheter tube (see Fig. 1.7).  (A) 
NO flux from surface of silicone rubber tubing over a 24 h period, with the applied -0.7 V (3 
min)/+0.2 V (3 min) (vs. NHE); pulse sequence initiated for 1 h every 2 h.  (B) Expanded view of 
2 h segment when voltage cycle is “off” and then turned “on” (oscillating between -0.7 V and +0.2 
V vs. NHE). (Reprint from Hofler et. al. RSC Adv. 2012, 2, 6765.)95  
 
1.4 Statement of Research 
The incomparable advantage of the electrochemical NO release method is the facile 
control of the NO release profile, which can not only extend the lifetime for NO release 
from medical devices when continuous NO release is not necessary (e.g., urinary catheters), 
but also provide a powerful tool for fundamental research on the dosage effect of NO.  The 
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frequent presence of wire electrodes in medical devices such as pacemakers, and 
temperature sensing catheters suggests that incorporation of the electrochemical NO 
release system into medical devices is practical and feasible. 
The purpose of this dissertation is to further improve and test the current copper 
wire-based electrochemical NO release system, and to develop a completely new 
electrochemical NO release systems using water-soluble Cu(II)-ligand catalysts that mimic 
the bacterial nitrite reductase.  This dissertation also aims to apply these electrochemical 
NO release systems to various medical devices to reduce clotting and infection.  It should 
be noted that this dissertation is prepared using a multiple manuscript/publication format, 
and hence the introduction sections in the chapters may be somewhat repetitive.  
Chapter 2 will discuss the improvement of the Cu0 wire electrode-based 
electrochemical NO release system first developed by Hofler et. al.,95 and demonstrate its 
in vivo anticlotting ability/activity in a catheter model. This work was published in 
Bioelectrochemistry (H. Ren, A. Colletta, D. Koley, J. F. Wu, C. W. Xi, T. C. Major, R. H. Bartlett, 
M. E. Meyerhoff, Bioelectrochemistry 2015, 104, 10-16).   
Chapter 3 focuses on utilizing a copper(II) tri-2-pyryidalmethylamine (CuTPMA) 
complex as a catalyst for electrochemical NO generation from inorganic nitrite.  The study 
of the catalytic effect using cyclic voltammetry, the control of NO release profile by 
different applied voltages, and the application of this new catheter system in anti-biofilm 
and anti-clotting (in vivo) experiments will be presented.  This work was published in ACS 
Applied Materials and Interfaces (H. Ren, J. Wu, C. Xi, N. Lehnert, T. Major, R. H. Bartlett, 
M. E. Meyerhoff, ACS Applied Materials & Interfaces 2014, 6, 3779-3783). 
Chapter 4 will demonstrate the incorporation of the newly developed 
electrochemical NO release system (Chapter 3) into a catheter-type PO2 sensors.  Both 
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bench top validation and in vivo experiments in veins and arteries of rabbit and pig models 
are described.  This work was published in Analytical Chemistry (H. Ren, M. A. Coughlin, 
T. C. Major, S. Aiello, A. Rojas Pena, R. H. Bartlett, M. E. Meyerhoff, Analytical Chemistry 2015, 
87, 8067-8072.). 
Chapter 5 will further utilize the advantage of facile control of the NO release 
profile enabled by the new electrochemical NO release system to study the dosage effect 
of NO on mature Pseudomonas aeruginosa biofilms.  The synergy between NO release 
and antibiotic treatment in creating a powerful antibiofilm strategy will also be examined 
experimentally and the results discussed in detail.  The work presented in this chapter has 
been submitted to Journal of Antimicrobial Chemotherapy (2016).  
Chapter 6 will detail the experimental and simulation studies of NO transport 
properties through different biomedical grade polymers and discusses the compatibility of 
these polymers with the new electrochemical NO release system.  Finite element analysis 
(FEA) is used to simulate the distribution of NO around catheters of different design.  Such 
FEA can help better understand and design NO release catheters and other devices. 
Chapter 7 will focus on the development of an NO inhalation (INO) device using 
the electrochemical NO release method.  A constant voltage method and a constant current 
method will be compared and the gas phase product composition will be examined.  This 
INO device can serve as a potential substitute for the expensive NO gas tanks for inhalation 
therapies in hospitals as well as portable INO device at home.  
Chapter 8 will summarize the major conclusions from this dissertation and provide 
suggestions for future directions. 
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Finally, Appendix A will outline the preliminary studies of other Cu(II)-ligand 
complexes for electrochemical NO generations from nitrite.  Catalyst efficiency, turnover 
number, as well as long-term stability will be discussed.  
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CHAPTER 2.  
 
 
OPTIMIZATION OF CU0 WIRE-BASED ELECTROCHEMICALLY 
MODULATED NO RELEASE FROM INORGANIC NITRITE  
 
2.1 Introduction 
As described in Chapter 1, catheters play an indispensable role in facilitating 
infusion, drug administration and drainage for hospitalized patients every day.  However, 
these biomedical devices also provide a potential source of entry for microbes into the 
human body that can lead to severe infection, the most common being catheter-associated 
bloodstream infections (CABSIs) and catheter-associated urinary tract infections 
(CAUTIs).1  It has been estimated that 250,000 cases of CABSIs2 and 500,000 incidences 
of CAUTIs3 occur in hospitals annually in the U.S., thus contributing considerably to 
increasing healthcare costs.4  Some 80% of CABSIs and CAUTIs are associated with 
biofilm formation, thus representing a significant challenge to many clinical treatments, 
especially conventional antibiotic therapies.5  Indeed, since the extracellular polymeric 
matrices of biofilms protect bacterial cells, most antibiotic treatments are ineffective.6  
Several strategies, such as modified surfaces,7 silver particle doped materials8,9 and anti-
quorum sensing drugs10,11 have been suggested over the last decades to either prevent or 
exterminate biofilms.  Yet, the problem of biofilm formation and concomitant catheter 
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induced infections persists, suggesting that other novel and more effective strategies are 
needed. 
In the case of intravascular catheters, another significant health risk factor is the 
activation of the clotting cascade and formation of surface thrombus, which can occlude a 
lumen of the catheter, potentially leading to complete dysfunction of the device and 
establishing risk for life-threatening complications via thrombus dislodgment.12,13  This 
problem is currently managed by injecting intermittent heparin “lock” solutions into the 
catheters.  Unfortunately, this approach increases the risk of systemic anticoagulation 
(mostly due to inadvertent overdoses) and heparin allergic response (e.g., heparin induced 
thrombocytopenia). 
Nitric oxide (NO) releasing catheters provide a promising solution to both the 
biofilm-induced infection and thrombosis issues that plague current biomedical catheters.  
Endothelial cells produce NO to attenuate platelet activation, adhesion, and aggregation.  
Hence, the use of NO release agents can be useful in developing therapeutic strategies that 
aim to avert arterial thrombotic disorders.14  This free radical gas molecule is also a 
principle component of the innate immune system and functions as a potent antimicrobial 
agent.  Indeed, macrophages release high levels of NO as cytotoxic agent to efficiently 
neutralize bacteria, viruses and helminths.15  Recent studies have also demonstrated that 
NO, in small doses, can act as a signaling molecule to disperse biofilms.16  Thus, with the 
goal of preventing implant-associated infections, several approaches have been developed 
to deliver NO by either doping or modifying polymeric materials with S-nitrosothiols 
(RSNO) or diazeniumdiolate-based NO donors.  These NO releasing materials have been 
shown to exhibit effective antibacterial properties.17-19  Nevertheless, the innate drawback 
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of these NO donor-based approaches is their instability, with RSNOs being sensitive to 
light and heat20 and diazeniumdiolates being very susceptible to decomposition by moisture 
and potentially yielding toxic nitrosamines.21,22  These issues have impeded their 
commercialization within medical devices. 
Instead of S-nitrosothiols and diazeniumdiolates, inorganic nitrite is a much more 
attractive NO source because of its low cost and high stability.  Recently, we reported the 
first electrochemical NO release approaches from a reservoir of inorganic nitrite by 
generating copper(I) species, from either a copper wire electrode or a water soluble copper 
complex.23,24  In the copper wire electrode-based system, the electrode material is cost-
effective but it suffered from low NO flux and large fluctuations in the NO release profile.  
The soluble copper complex system releases a more steady and tunable NO flux, but 
platinum or gold wires were used as electrode materials, which are too expensive for 
widespread commercial use.  Herein, we describe an electrochemical pulse sequence 
applied to a Cuo wire working electrode within a single lumen catheter model that achieves 
a more stable, higher flux and longer-term NO generation.  The NO can be easily released 
on demand by turning “on” electrochemical pulse sequence, and the flux of NO can be 
modulated by applying different voltage pulses to the copper working electrode, which 
cannot be achieved by traditional chemical release.  By employing this method to fabricate 
catheters, the NO flux from the catheter surface is increased by 100% compared with the 
earlier electrochemical system, and this enables successful in vivo demonstration of the 
thromboresistance of catheters prepared with the Cu0 wire electrode-based catheter system.  
Further, we clearly show that by using different electrochemically modulated NO release 
profiles (compared to that reported in23), the model catheters are able to prevent biofilm 
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formation by CABSIs-inducing bacterial species.  It is also demonstrated, for the first time, 
that only 3 h of electrochemically generated NO from the catheter surfaces can significantly 
disperse 2 d and 4 d old pre-formed biofilms by an E. coli bacterial strain that is well known 
to be associated with CAUTIs. 
 
2.2 Experimental Details 
2.2.1 Materials 
Sodium nitrite, sodium chloride, ethylenediaminetetraacetic acid (EDTA) disodium 
salt, sodium phosphate dibasic heptahydrate, and sodium phosphate monobasic 
monohydrate were purchased from Sigma-Aldrich (St. Louis, MO) and used as received.  
Luria Bertani (LB) broth and LB agar were obtained from Fisher Scientific Inc. (Pittsburgh, 
PA).  All aqueous solutions were prepared with deionized water from a Milli-Q system (18 
MΩ cm-1; Millipore Corp., Billerica, MA). 
Polytetrafluoroethylene (PTFE)-coated silver wire (bare wire 0.125 mm o.d.; PTFE 
coated wire 0.176 mm o.d.) was purchased from Sigmund Cohn Corp. (Mount Vernon, 
NY).  PTFE-coated Cuo wire (bare wire 0.127 mm o.d.; PTFE coated wire 0.152 mm o.d.) 
was a product of Phoenix Wire Inc. (South Hero, VT).  Single-lumen standard silicone 
tubing (0.51 mm i.d.; 0.94 mm o.d.) was purchased from Helix Medical (Carpentaria, CA).  
Silicone rubber sealant was obtained from Dow Corning (Midland, MI). 
E. coli K-12 MG16653 and S. aureus ATCC 45330 were from the American Type 
Culture Collection. 
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2.2.2 Catheters Fabrication 
The model catheter configuration consisted of a single-lumen, silicone rubber 
tubing (length: 3 cm), that was sealed at one end with silicone rubber sealant.  A PTFE 
coated silver/silver chloride wire was utilized as the reference electrode (with 0.235 cm2 
surface area exposed) and a PTFE-coated Cuo wire (with ~0.012 cm2 surface area exposed) 
served as the working electrode within the lumen.  The reservoir solution within the tubing 
was 1.0 M NaNO2, 0.30 M NaCl, 0.02 M EDTA, 1.0 M phosphate buffer (pH 7.05).  The 
PTFE was removed from the ends of both Ago and Cuo wires to expose a length of 60 mm 
and 3 mm, respectively.  Both wires were coiled and inserted in the lumen in a manner that 
prevents direct metallic contact with each other.  Finally, the other end of the silicone 
rubber tubing was sealed with silicone rubber sealant, and left to cure in water for 
approximately 12 h.  
2.2.3 Electrochemical Generation of Nitric Oxide 
The NO releasing profile from each catheter was measured via a 
chemiluminescence NO analyzer (NOA) (Sievers 280, Boulder CO).  The catheter was 
placed inside a glass cell, containing DI water; the solution was constantly purged with a 
stream of N2 gas, and the electrochemically generated NO emitted from the outer surface 
of the catheter tubing was carried to the NOA.  The Cuo and Ago wires coming out of the 
catheters were connected to a portable potentiostat (CH Instruments 1206B, Austin TX).  
To generate NO, a voltage pulse sequence was applied to the Cuo wire working electrode.  
One cycle of the pulse sequence included a period of a cathodic pulse (-1.1, -1.2, -1.3 or -
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1.4 V vs. Ag/AgCl wire), and another period involved an anodic pulse (+0.2 V vs. Ag/AgCl 
wire). 
2.2.4 In Vivo Anti-Thrombotic Experiment in Rabbits 
Briefly, one group of NO releasing catheters (low flux group, n=3) was tested using 
pulse sequence of 15 s at -1.25 V and 15 s at +0.20 V and the other group (high flux group, 
n=3) was tested using a pulse sequence of 15 s at -1.3 V and 15 s at +0.20 V.  Two or three 
catheters were implanted into the jugular and/or femoral veins of each rabbit (~ 3 kg).  One 
of the catheters was turned “on” by applying a pulse sequence described above and the 
other was turned “off” with open circuit.  After 7 h, the catheters were explanted, a digital 
picture was taken, and the red pixels were counted using Image J software to represent the 
clot area.  Animal handling and surgical procedures were approved by the University 
Committee on the Use and Care of Animals in accordance with university and federal 
regulations and a detailed protocol was reported elsewhere.24 
2.2.5 Biofilm Growth Conditions and Plate Counting 
S. aureus biofilms. Staphylococcus aureus ATCC 25923 was used for the test.  
Catheters were mounted aseptically in the middle of a drip flow bioreactor (DFR 1110-4, 
BioSurface Technologies, Bozeman, MO) chambers.  Each reactor chamber including the 
catheter was initially innoculated with 10 mL of a 100 fold-diluted bacterial culture that 
had been grown overnight with shaking at 37 ̊C. After one hour incubation, fresh 10% 
strength of LB broth was dripped into the flow chamber at a flow rate of 100 mL/h.  
Biofilms were grown for 48 h at 37 ̊C, by utilizing the drip flow biofilm reactor.  The 
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channels of the reactor were constantly flushed with 10% LB broth for the entire time of 
the biofilm growth.  Nitric oxide release was turned “on” during the 48 h experiment by 
applying cycles of 15 s at -1.3 V and 15 s at +0.2 V.  At the end of the 48 h, each catheter 
was removed from the drip flow biofilm reactor and placed separately into a centrifuge 
tube containing 2 mL of 10 mM phosphate buffer saline, pH 7.4 (PBS).  Each catheter was 
then homogenized in order to disintegrate the biofilm clumps and form a homogeneous cell 
suspension.  Finally, each sample was 10-fold serially diluted and plated using the spread 
plating technique to assess cell viability.   
E. coli biofilms. Escherichia coli K-12 was used for this test.  The bacterial strain 
was grown for either 48 or 96 h at 22 ̊C with catheters in the channel of the reactor but not 
turned “on” with the applied voltage pulse sequence.  This specific temperature was chosen 
as it allowed E. coli biofilms to develop that had greater thickness and biomass.  At the end 
of the 48 or 96 h, NO release was turned “on” for 3 h by applying cycles of 15 s at -1.3 V 
and 15 s at +0.2 V.  The other growth conditions were the same as those used for S. aureus 
biofilms.  Procedures to assess cell viability were also performed exactly as described 
above. 
2.2.6 Biofilm Imaging 
After either 2 or 4 d of biofilm growth, the NO releasing and control catheters (same 
assembly as NO release but electrodes in the catheters were not connected to potentiostat) 
to be used for fluorescence imaging were removed from the drip flow biofilm reactor and 
gently rinsed with 10 mM PBS.  Unlike catheters utilized for plate-counting, these catheters 
were not homogenized; instead, they were stained with fluorescent dyes by using 
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Live/Dead BacLight Bacterial Viability kit (Invitrogen, Carlsbad, CA) for 20 min in the 
dark, exactly per the kit’s instructions.  Finally, each catheter was singly placed onto a 
cover-slip and its outer surface was visualized using an inverted fluorescent microscope 
(Olympus 1X71, Center Valley, PA), equipped with the appropriate filter sets. 
 
2.3 Results and Discussion 
2.3.1 Electrochemical Generation of Nitric Oxide 
 
Figure 2.1. Schematic of a single-lumen electrochemically modulated NO releasing catheter. 
 
The model catheter configuration consists of a single-lumen silicone rubber tubing 
that contains a nitrite reservoir and Cu0 and Ag/AgCl wire electrodes (Figure 2.1).  A pulse 
sequence of applied voltages to the Cuo wire electrode is used to generate NO continuously 
from the nitrite ion reservoir within the catheter.  The anodic pulse provides a transient 
level of Cu(I) ions that are capable of reducing nitrite to NO in accordance with the 
following reaction: 
Cu(I) + NO2
- + 2 H+ → Cu(II) + NO + H2O 
NONONO
NONONO
Ag/AgCl 
electrode
Cu electrode PTFE coating
nitrite 
reservoir
silicone rubber
potentiostat
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However, oxidation of the copper electrode surface forms oxides of copper that 
passivate the surface, requiring applied cathodic voltages to regenerate a clean Cuo surface 
that can create more Cu(I) ions upon re-oxidation.23  Therefore, the pulse sequence of 
applied voltages must include repeated cycles of a cathodic voltage pulse followed by an 
anodic pulse (Figure 2.2a).  In earlier work,23 a pulse sequence containing cycles of 3 min 
at -0.92 V and 3 min at 0 V(vs. Ag/AgCl) was used to generate an average NO flux of 0.5 
× 10-10 mol min-1 cm-2, which fluctuates periodically from (0.25–0.75) × 10-10 mol min-1 
cm-2 (see Figure 2.2b).  This NO flux is not sufficient to prevent clotting in vivo and the 
fluctuation complicates the interpreting the relationship between NO flux and in vivo 
results.  In order to obtain higher and more stable NO fluxes, in this work the effect of 
different pulse sequences on the NO release profile were compared.  By using the pulse 
sequence of +0.2 V and -1.3 V, the average measured NO flux is now consistently >1.0 × 
10-10 mol min-1 cm-2 (in absence of significant levels of oxygen, see below).  As shown in 
Figure 2.2c, it is evident that fluctuations of the NO release profile are much larger if the 
pulse cycle time is every 6 min as compared with every 30 s.  Note that for pulse cycles of 
every 6 min for 2 h, 20 spikes can be identified from the NO release profile detected by the 
NOA.  This is because NO is only generated on the electrode during the anodic pulse—
which is half of the cycle.  
In another experiment, it was found that by further increasing the cathodic voltages 
from -1.0 V to -1.4 V (vs. Ag/AgCl wire), increased NO fluxes from the surface of the 
catheter tubing could be obtained (Figure 2.3).  This is likely due to the fact that the more 
negative voltage can better regenerate a clean Cuo surface.  It was found that when cathodic 
pulses above -1.35 V are used, the baseline NO level (when the sequence is turned “off”) 
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also increases, probably due to the fact that the surface regenerated above this voltage is 
too active.  When cathodic pulses < -1.35 V are used, the NO baseline level is consistently 
low (<0.2 × 10-10 mol min-1 cm-2) when turned “off”.  Therefore, for remainder of the study, 
a pulse sequence with 15 s at +0.2 V and 15 s at -1.3 V was employed and with this 
sequence the catheters can release NO continuously for > 60 h (Figure 2.4).  
 
Figure 2.2.  Effect of pulse cycle on NO release profile from surface of the silicone catheter from 
a copper wire electrode: (a) Schematic of applied voltage pulse sequence; (b) NO release profile 
from 6 min cycles using old pulse sequence (as in ref 23);  with an anodic pulse of 3 min at 0 V 
and a cathodic pulse of  3 min at -0.92 V (vs. Ag/AgCl wire); (c) NO release profile of 6 min cycles 
and 30 s cycles, with an anodic pulse of  +0.2 V and a cathodic pulse of  -1.3 V (vs. Ag/AgCl wire). 
 
The effect of O2 level in the test solution in which the catheters were placed was 
also studied.  In the presence of 10% and 21% O2, the detected NO flux is reduced by 39% 
and 53%, respectively (Figure 2.5).  This decrease in measured NO can be the result of two 
processes.  First, the generated NO coming from the catheter can react with O2 directly, 
within the catheter and within the gas phase that is purging the NO into the 
chemiluminescence instrument.  Second, it is known that some Cu(I) species can reduce 
O2 to superoxide radical, which can scavenge NO to form peroxynitrite.
25  It should be 
noted that the O2 content in a vein is typically is much less than 10%, and within an artery 
anodic
cathodic
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it is fairly close to this level (e.g., corresponding to 80-120 mm Hg).  Hence, for the 
proposed catheters described here, it is likely that in vivo, the NO fluxes at the surface of 
the catheters should typically be > 0.8 × 10-10 mol min-1 cm-2, whether the catheters are 
implanted in veins or arteries. 
 
Figure 2.3. Effect of cathodic pulse voltage on NO release from a single-lumen catheter at 25 °C.  
Each pulse cycle includes a 15 s cathodic voltage pulse and a 15 s anodic voltage pulse.  The 
potentials are vs. Ag/AgCl wire. 
 
 
Figure 2.4. NO release from a single-lumen silicone catheter using repeated pulse cycles of 15 s at 
-1.3 V and 15 s at +0.2 V at 37 °C.  The dotted line indicates a surface NO flux of 1.0 × 10-10 mol 
min-1 cm-2.  Note that the catheter is intentionally turned “off” periodically to demonstrate the NO 
release can be modulated.  The potentials are vs. a Ag/AgCl wire. 
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Figure 2.5. Effect of solution phase O2 concentration on NO release from a single-lumen silicone 
catheter (37 °C).  Repeated pulse cycles of 15 s at -1.3 V and 15 s at +0.2 V are applied.  Note that 
NO release is turned “off” when changing the purging gas. 
 
2.3.2 Anti-Thrombotic Properties of NO Releasing Catheters In Vivo 
To assess the antithrombotic activity of the electrochemical NO releasing catheters, 
the devices (both active and control catheters) were implanted into rabbit veins for 7 h.  
Catheters in the low flux group were set to exhibit an NO flux of ~0.7 × 10-10 mol min-1 
cm-2 and those in the high flux group exhibit fluxes of ~1.1 × 10-10 mol min-1 cm-2 (via the 
applied voltage values for the cathodic pulse; see experimental section).  As shown in 
Figure 2.6a, less thrombus formation was observed on the surface of the NO releasing 
catheters as compared with control catheters.  However, the NO flux plays a critical role in 
this experiment, with a higher flux (~1.1 × 10-10 mol min-1 cm-2) reducing the overall 
thrombus coverage by 62% (n = 3, p < 0.001), while a lower flux (~0.7 × 10-10 mol min-1 
cm-2 reduces thrombus area by only 17% (Figure 2.6b; n = 3, p < 0.05) (reductions are 
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relative to average of control catheters without NO release).  This agrees well with the fact 
that the endothelium layer of cells on the inner walls of blood vessels produces NO at a 
flux in the range of (0.5–4) × 10-10 mol min-1 cm-2 to prevent clotting, and dysfunction of 
NO producing the enzyme, eNOS, increases susceptibility to thrombophilia.26  Note that 
NO released from the surface of the catheters has a short lifetime in blood (<1 s) due to 
reaction with oxyhemoglobin and, thus, will only induce a very localized antithrombotic 
effect, as compared with heparin, which usually induces a systemic effect.27 
 
Figure 2.6. Antithrombotic effect of NO releasing catheters (NRC) in 7 h rabbit experiment: a) 
representative photos of high flux (NRC (High) ~1.1 × 10-10 mol min-1 cm-2), low flux (NRC (Low) 
~0.7 × 10-10 mol min-1 cm-2) and control (Control, < 0.1 × 10-10 mol min-1 cm-2) catheters after 
explantation; b) thrombus surface coverage quantified by counting the red pixels on the catheters 
from the photos (Low flux catheters: n = 3 rabbits, * p < 0.05; High flux catheters: n = 3 rabbits, 
**p < 0.01). 
 
2.3.3 Biofilm Prevention Study 
 Since bacterial infections pose major clinical problem,28 in prior work with the Cu-
wire based NO release catheters, the effect of continuous e-chem NO release on the 
adhesion of E. coli and A. baumannii bacteria to the catheter surface within a CDC 
NRC(High)
Control
NRC(High)
NRC(High)
Control
Control
NRC(Low)
Control
NRC(Low)
b)a)
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bioreactor was examined.  In this study, a drip flow bioreactor is used to allow growth of 
high biomass-biofilms close to the air liquid interface, which provides a standardized 
model that better represents in vivo conditions.29  We first investigated the effect of NO on 
bacterial biofilm formation from a microbial species that is more prevalent with CABSI, S. 
aureus.  We also examined whether effective dispersal of preformed, mature biofilms can 
be achieved with only 3 h of NO release turned “on” after the catheters were placed in the 
drip flow bioreactor to allow E. coli biofilm formation of over 2 and 4 d periods.  
Since intravascular catheters necessitate continuous NO release to prevent clotting 
formation on their surfaces, biofilm dispersal was first studied by employing catheters that 
release NO continuously during the time exposed to S. aureus and media within the drip 
flow bioreactor.  The S. aureus biofilms were grown for 48 h at 37 ̊C, and NO was 
constantly generated electrochemically for the active catheters using pulse sequence of 15 
s at -1.3 V and 15 s at +0.2 V.  Corresponding controls containing the same nitrite reservoir 
as well as the Cuo and Ag/AgCl wires but not connected to the potentiostat were also 
examined.  Plate counts of viable bacteria present on the surface of the catheters 
demonstrate a 6 log-unit difference between control and NO releasing catheters (Figure 2.7; 
n = 3, p < 0.01). 
It should be noted that S. aureus is an opportunistic pathogen capable of forming 
biofilms and causing chronic infections with high morbidity and mortality.30,31  
Furthermore, because S. aureus biofilms are purported to promote horizontal transfer of 
antibiotic determinants, they present an even greater challenge to successfully eradicate.32  
Thus, since the NO releasing catheter devices significantly lower the viable cell count of 
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S. aureus biofilms, this approach may represent an efficacious and relatively simple 
strategy to reduce this current serious complication in hospitalized patients.  
 
Figure 2.7. S. aureus biofilms developed on single-lumen catheters in a drip flow biofilm reactor 
for 48 h with the electrochemical NO release turned “on” continuously (only for NO release 
catheters) throughout the entire period of the biofilm growth.  Plate counts of viable bacteria 
attached to the catheter surface after this period (n = 3, **p < 0.01). 
 
It is also interesting to note that some bacterial infections can cause concomitant 
thrombosis.  Indeed, invasive staphylococcal and streptococcal bacterial infections can 
promote hemostatic system malfunctions, which also lead to thrombosis.33,34  Colonization 
by S. aureus, in addition to causing the majority of intravascular catheters-related 
infections,35 can also induce platelet aggregation in vitro and induce the development of 
deep vein thrombosis in vivo.36,37 
Because the plate count data for S. aureus biofilms showed a dramatic difference 
between continuous NO releasing and the control catheters, this result prompted an 
investigation into whether releasing NO only at the end of the biofilm growth period may 
still be sufficient to reduce bacterial viability on the surface of the catheter.  Moreover, this 
strategy would conserve the nitrite reservoir, thereby significantly increasing the 
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operational NO release lifetime of any medical catheters developed based on this chemistry.  
This approach could be more viable for urinary catheters rather than intravascular devices, 
since thrombosis would not be an issue with such catheters and hence continuous NO 
release would not likely be required. 
 
Figure 2.8. E. coli biofilm developed on single-lumen catheters in a drip flow biofilm reactor for 
a) 48 h and b) 96 h and NO release was then turned “on” only at the end of these periods for 3 h.  
Plate counts of viable bacteria attached to the catheter surface (n = 4 for both experiments, **p < 
0.01). 
 
Since E. coli is the cause of 80% of urinary tract infections (UTIs) in humans38 and 
can easily adhere onto abiotic surfaces and mediate strong biofilm growth,39,40 this 
bacterium was chosen to assess whether the catheters that are only turned “on” to generate 
NO at the end of the biofilm maturation process, can still abate cell viability significantly.  
Remarkably, as shown in Figure 2.8a, the electrochemical NO-release catheters can 
efficiently disperse 48 h E. coli biofilms by generating NO for only 3 h at relevant 
biological fluxes (1.0 × 10−10 mol min−1 cm−2).  Indeed, the bacterial count on the surface 
of the NO producing catheters is 3 log units lower than that found on the control catheters 
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(n = 4, p < 0.01).  This finding is further validated by the fluorescent imaging data which 
illustrates that the bacterial surface coverage of the NO releasing catheters is noticeably 
less than the control catheters (Figure 2.9). 
 
Figure 2.9. Representative fluorescent micrographs of surfaces of a) control and b) NO releasing 
catheters with live/dead staining.  E. coli biofilms was grown for 48 h and NO is turned “on” for 
the NO releasing catheter for 3 h at the end of the growth before the imaging. 
 
The matrix of extracellular polymeric substances, by increasing over colonization 
time, contributes to the adhesion properties of bacteria and enhances biofilm stability.41-43  
Because of this, both dispersal and eradication of biofilm structures are typically more 
problematic at later stages of biofilm development.  Nonetheless, as demonstrated here, the 
electrochemical method of NO production from the surface of a catheter is efficient at 
inducing dispersal of 96 h old E. coli biofilms (Figure 2.8b).  In fact, it is shown that the 
bacterial counts on the surfaces of catheters releasing NO for 3 h after a 4 d growth of 
biofilms are almost 3 log units lower than those on the control catheters (n = 4, p < 0.01).  
Consequently, these results demonstrate how the electromodulated NO releasing approach 
may also provide a novel strategy to reduce biofilm-induced UTIs over an extended time 
period of catheter placement, via a periodic generation of NO. 
a)                       b)
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Because the proposed electrochemical NO generating system has considerable anti-
biofilm properties, in future studies, it would be interesting to investigate whether local NO 
delivery at these low, non-toxic fluxes can also be efficient against antibiotic resistant, 
biofilm-forming microbial isolates.  It has already been shown that NO can have an 
antimicrobial effect against multidrug-resistant uropathogenic E. coli.44  In addition, a 
manganese nitrosyl, entrapped in the mesoporous material MCM-41, has been discovered 
to strongly inhibit the growth of drug-resistant A. baumannii.45  Nevertheless, most of these 
studies to date have focused on the bactericidal properties of NO on planktonic cells.  
Because cells within biofilms are much more resistant than planktonic cells to 
antimicrobial agents,6,46 it will be necessary to investigate whether NO released from the 
catheter configuration described in this work can also eradicate antibiotic-resistant isolates 
that have been grown to a mature biofilm stage on the surface of such devices.  
 
2.4 Conclusions 
In summary, it has been demonstrated that electrochemical release of NO from 
model catheters, which employ a copper wire electrode to generate Cu(I) ions to reduce 
nitrite to NO, can produce a relatively steady flux of NO from their surfaces for an extended 
time period by using the proper applied voltage pulse sequence.  Such catheters were 
further shown to exhibit significant thromboresistance in vivo as well as anti-biofilm 
properties against bacteria that are known to be associated with high rates of hospital 
infections for both intravascular and urinary catheters.  It should be noted that the single-
lumen configuration used in this work is not practical for preparing operational catheters 
that could be employed clinically to infuse fluids or withdraw blood.  However, we have 
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already demonstrated that electrochemical NO generation from multi-lumen catheters is 
possible, using the alternate Cu(II)-ligand mediated electrochemical reduction of nitrite 
within one lumen of the multi-lumen device.24  Hence, efforts will now focus on using 
either of the two methods (Cuo wire-based or Cu(II)-complex based) within full sized 
multi-lumen catheter configurations to demonstrate the anti-clotting and antimicrobial 
capability of this new approach with both intravascular and urinary catheters that could 
ultimately be employed in human studies. 
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CHAPTER 3.  
 
 
ELECTROCHEMICALLY MODULATED NO RELEASING BIOMEDICAL 
DEVICES VIA COPPER(II)-TRI(2-PYRIDYLMETHYL)AMINE MEDIATED 
REDUCTION OF NITRITE 
 
3.1 Introduction 
Biomedical devices are central to everyday medical care and intravascular catheters, 
in particular, play an indispensable role in monitoring patients by providing access to the 
blood and enabling infusion of drugs and nutrients.  However, there are two major 
complications associated with the use of such devices; microbial infections and 
thrombosis/clotting.  An estimated 80,000 catheter-related bloodstream infections (CR-
BSIs) occur in patients within intensive care units (ICUs) in the United States each year, 
causing as many as 28,000 deaths and $2.3 billion in additional medical costs.1  Thrombosis 
(i.e. clotting) is another major issue associated with catheter use, and this problem is only 
partly circumvented by intermittent or continuous heparin infusion.  Additionally, use of 
heparin poses risk of systemic anticoagulation as well as heparin sensitivity in certain 
patients (including heparin induced thrombocytopenia (HIT)).  Further, use of heparin does 
not prevent platelet activation and adhesion, the primary events in a foreign body induced 
coagulation process.2  
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Nitric oxide is an endogenously produced molecule (endothelial cells produce NO 
at a flux of (0.5–4.0) × 10-10 mol min-1 cm-2) 3 that exhibits exceptional therapeutic potential, 
including killing bacteria4 and preventing thrombosis.5  Its short lifetime in blood (seconds) 
is both beneficial and challenging as the short-lived radical NO will only have a localized 
effect.6  Thus, appropriate storage and delivery methods must be carefully considered as 
NO should be released precisely to a given area where it is needed.  Strategies of doping 
NO donors such as diazeniumdiolates and S-nitrosothiols within polymer matrices have 
created new materials that exhibit improved biocompatibility in various in vivo blood 
contacting device/applications.7,8  However, such NO donors are fragile and can lose NO 
during storage as a result of increased temperature or exposure to moisture or light.  This 
increases the cost required for shipping and storage, limiting their utility in commercial 
biomedical products.  
Nitric oxide generation via electrochemical reduction of nitrite could provide a 
cheap and controllable alternative method.  However, direct nitrite reduction on metal 
electrodes is complicated and the products can vary from NO, N2O, N2, NH2OH to NH3, 
depending on pH, nitrite concentration, potential applied and nature of the metal electrode 
itself.9,10  To achieve high selectivity towards NO generation, catalysts are necessary.  Iron 
meso-tetrakis(4-N-methylpyridiniumyl) porphyrin has been shown to produce NO in a two-
step electrolysis method in a flow system.11  Recently, it was demonstrated that Cuo 
electrodes can be used to generate NO from nitrite, via a pulsed applied potential 
sequence.12  The sequence involved an anodic pulse to generate Cu(I) species and a 
subsequent cathodic pulse to clean the electrode. 
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Herein a simpler and much more attractive method to generate NO from a reservoir 
of nitrite ions is demonstrated using constant potential electrochemistry and the technique 
is applied to fabricate antithrombotic/antimicrobial catheters.  In nature, Cu-containing 
nitrite reductases (E.C. 1.7.99.3) found in bacteria convert nitrite to NO via a 1 electron 
reduction.13  Many Cu(II) complexes have been studied to mimic the active site of this 
enzyme,14,15 as well as detect NO via fluorescence,16 and several Cu(I) model systems have 
been shown to mediate nitrite reduction to NO.17–19  In addition, Cu(II)-tri(2-
pyridylmethyl)amine (Cu(II)TPMA) has been reported to catalyze the electrochemical 
reduction of nitrite to produce primarily N2O.
20  In the present work we demonstrate that 
conditions can be tuned for this Cu(II)TPMA species to electrochemically generate 
predominately NO. 
 
3.2 Experimental Details 
3.2.1 Chemicals and Materials 
Sodium nitrite, sodium chloride, sodium phosphate dibasic (99.95%), sodium 
phosphate monohydrate (99.5%), 3-(N-morpholino)propanesulfonic acid (99.5%), 3-(N-
morpholino)propanesulfonic acid sodium salt (99.5%), copper(II) acetate monohydrate 
(99.99%), and tri(2-pyridylmethyl)amine (98%) were purchased from Sigma-Aldrich (St. 
Louis, MO) and used as received.  
PTFE coated platinum (0.125 mm) and silver (0.127 mm) wires were purchase from 
Sigmund Cohn Corp. (Mount Vernon, NY).  Single lumen standard silicone tubing (o.d. 
1.47 mm, i.d. 1.96 mm) was purchased from Helix Medical (Carpentaria, CA) while dual 
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lumen silicone catheters (o.d. 2.34 mm) were provided by Cook Medical (Bloomington, 
IN). 
Bacteria: E. coli EBW25113 was grown at 37 °C in Luria Bertani (LB) broth or LB 
agar plates. LB broth of 10% strength was used for biofilm development. 
3.2.2 Bulk Solution Electrochemical Experiments 
All electrochemical experiments were performed using a CH Instrument 1206B 
potentiostat. CVs were acquired in 5 mL of stationary solution in a three-electrode 
arrangement with a disk working electrode, Pt coil counter electrode and Ag/AgCl (3 M 
Cl-) reference electrode.  
Bulk electrolysis with different applied potentials were performed in a cell 
containing 5 mL solution of 2 mM Cu(II)TPMA, 100 mM nitrite and 0.1 M MOPS buffer.  
The gas product was then swept into a nitric oxide analyzer (NOA Sievers 280i, GE).  The 
schematic of experiment setup is shown below in Figure 3.1. 
 
Figure 3.1. Experiment setup for bulk electrolysis of Cu(II)TPMA and nitrite solution. 
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3.2.3 Catheter Fabrication 
A single lumen silicone rubber tubing (7.5 cm length, inner diameter 1.47 mm, and 
outer diameter 1.96 mm) was sealed at one end with silicone rubber sealant.  A 
polytetrafluoroethylene (PTFE)-coated silver/silver chloride wire (with 0.080 cm2 surface 
area exposed) was used as the reference electrode, and a PTFE-coated platinum wire (with 
0.039 cm2 surface area exposed) was used as the working electrode.  The exposed ends of 
the respective wires were coiled separately.  The coiled ends were inserted into the single 
lumen silicone rubber tubing so that the silver/silver chloride wire and the copper wire were 
not in direct metallic connection.  A solution was loaded into the single lumen silicone 
rubber tubing.  The solution included 2 or 4 mM Cu(II)TPMA, 0.4 M NaNO2, and 0.2 M 
NaCl in 0.5 M MOPS buffer (pH 7.2).  The silicone rubber tubing was then sealed to form 
a catheter.  The PTFE-coated silver/silver chloride wire and PTFE-coated Pt wire extended 
out of the silicone rubber tubing as respective leads to the reference and working electrodes.  
A duel lumen catheter may be formed in a similar manner by introducing the solution and 
electrode into one of the two available lumens. 
3.2.4 Gas Phase IR Experiment 
A cell containing 10 mL of different concentrations of nitrite (50, 100 200 and 400 
mM) in 2 mM CuTPMA, 0.2 M NaCl and 0.5 M MOPS buffer (pH 7.2) was used for bulk 
electrolysis.  The solution was purged with Ar for 30 min before each experiment.  A Pt 
wire electrode (0.32 cm2) was used as working electrode and Ag/AgCl wire as reference 
and counter electrode. A constant potential (-0.4 V vs. 0.2 M Ag/AgCl) was applied for 3 
h with stirring, after which the headspace gas was transferred into a vacuumed gas phase 
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IR cell using a cannula and analyzed using a Perkin-Elmer FT-IR.  A prior calibration curve 
was obtained by adding different known amounts of saturated N2O solution into 10 mL 0.5 
M MOPS buffer (pH 7.2) to make 0.25, 1, 2 and 2.5 mM N2O.  Headspace N2O was 
analyzed similarly and quantification was achieved by integration the N2O feature peaks at 
2235 and 2212 cm-1 in the IR spectra.21 
3.2.5 Rabbit Experiments 
Animal handling and surgical procedures were approved by the University 
Committee on the Use and Care of Animals in accordance with university and federal 
regulations and the detailed protocols are reported elsewhere.22  Briefly, two catheters were 
implanted into the left and right jugular veins of ca. 3 kg anesthetized rabbits.  The animals 
received no other anticoagulant or anti-platelet agent during the experiment.  One of the 
catheters was “turned on” by applying a - 0.4 V vs. 0.2 M Cl- Ag/AgCl reference and the 
other “turned off” with no potential applied.  After 7 h, the catheters were explanted and a 
digital picture was taken and the red pixels were counted using Image J software to 
represent the clot area. 
3.2.6 Numeric Simulation 
Simulation was performed using COMSOL 4.3 b.  To determine the NO 
distribution around the dual lumen catheter, a 2D space simulation was performed using 
the cross sectional geometry of the catheter.  Since the catheter has a large length to 
diameter ratio, the edge effect of the two ends of the catheter can be neglected. 
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For NO distribution along the single lumen catheter, 2D-axial symmetry space was 
used.  An NO flux of 7.4 × 10-9 mol min-1 cm-2 was set from the electrode surface in both 
cases, which is calculated based on NO release experimental data from the NOA.  A 
diffusion profile with no convection is set with the stiff spring boundary condition across 
the solution-polymer phase boundary, which is used to ensure a continuous flux with 
partitioning of NO between the two phases (solution and polymer).  Key boundary 
conditions and parameters are listed in Table 3.1.  The diffusion and partition coefficients 
are based on literature data.23-25 
 
Table 3.1. Boundary conditions used for simulating the NO diffusion from electrode surface 
through silicone rubber. 
Boundary/ Domain Boundary Conditions 
Electrode surface N1 = 7.4 × 10-9 mol min-1 cm-2 
Inner solution DNO_water 
Inner solution-silicone N2 = 1000 × (K*c1-c2) 
Silicone DNO_silicone 
Silicone-outer solution N3 = 1000 × (c2-K*c3) 
Outer solution DNO_water 
 
N1 is the flux of NO from electrode surface. N2 is the flux of NO from the inner solution (Cu(II)TPMA 
and nitrite solution) into the silicone rubber.  N3 is the flux of NO from silicone rubber into the outer 
solution phase. DNO_water and DNO_silicone are the diffusion coefficient of NO in water and silicone rubber, 
respectively. K is the diffusion coefficient of NO in silicone phase over water phase. 
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3.2.7 ICP-OES Experiment 
Nitric oxide releasing single lumen catheters were turned on (-0.4 V) and soaked in 
3 mL PBS (pH 7.4) for 7 days (n = 3).  The Cu content in both soaking PBS solution and 
the native PBS solution was detected by ICP-OES (inductively coupled plasma optical 
emission spectroscopy) and quantified via a calibration curve method.  
 
3.3 Results and Discussion 
 
Figure 3.2. Cyclic voltammograms of 1 mM Cu(II)TPMA in 0.1 M MOPS buffer (pH 7.2) on a 
0.0314 cm2 gold disc electrode with different levels of nitrite in solution saturated with N2.  Scan 
rate is 50 mV/s.  Inset: structure of Cu(II)TPMA. 
 
Figure 3.2 shows the structure of Cu(II)TPMA (inset) and the resulting cyclic 
voltammetry (CV) of Cu(II)TPMA on a gold (Au) electrode in the presence of different 
levels of nitrite in solution.  The reversible peaks in the absence of nitrite correspond to a 
one electron reduction from Cu(II) to Cu(I) within the complex, and the characteristic 
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catalytic peak in the presence of nitrite indicates that the nitrite is reduced by the Cu(I) 
species.  The CVs observed are similar on platinum (Pt) and glassy carbon electrodes 
(Figure 3.3).   
 
Figure 3.3. Cyclic voltammograms of 1 mM CuTPMA in 0.1 M MOPS buffer (pH 7.2) in a bulk 
solution experiment using a) 0.0707 cm2 glassy carbon (GC) disk electrode; and b) 0.0314 cm2 
platinum disc electrode with different levels of nitrite in N2 environment.  Scan rate: 50 mV/s. 
 
To detect the NO product, a bulk electrolysis experiment was performed by 
applying cathodic potentials in a cell that is connected to a chemiluminescence nitric oxide 
analyzer (NOA).  A pH 7.2 3-(N-morpholino)propanesulfonic acid (MOPS) buffer was 
used for these experiments, since at a pH lower than 6, nitrite disproportionation occurs, 
producing background NO and NO2.  At pH higher than 8, it was observed that the activity 
of the catalyst decreases significantly and nitric oxide is not detected.  Figure 3.4 
demonstrates that a low, medium and high flux of NO release can be modulated by applying 
-0.2 V, -0.3 V and -0.4 V, respectively, to the working electrode (vs. 3 M Ag/AgCl 
reference electrode).  
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Figure 3.4. Modulation of NO generation in bulk solution by applying -0.2 V, -0.3 V and -0.4 V 
(vs. 3 M Cl- Ag/AgCl) on a 0.071 cm2 GC electrode.  The solution contains 2 mM Cu(II)TPMA, 
100 mM nitrite and 0.1 M MOPS buffer (pH 7.2). 
 
To clarify the difference in product composition with an earlier paper20 where N2O 
was found to be the dominant product, bulk electrolysis experiments were performed.  In 
these experiments, different levels of nitrite were present while applying a constant 
potential for 3 h, followed by careful analysis of the N2O content by gas phase IR.  It was 
found that N2O is produced (from the reaction of Cu(I)TPMA with NO) but can be 
suppressed to a relatively low level (< 6%) when higher concentrations of nitrite are 
employed (see Figure 3.5 and Table 3.2).  Note this low amount of N2O is quite safe since 
up to 70% N2O by volume is used routinely as an inhalation anesthetic in dentistry.
26  
Previous studies have shown that Cu(I) complexes can disproportionate NO to generate 
N2O and NO2.
27,28  It is believed that the excess nitrite used in these experiments 
competitively binds to the Cu(I/II) center of the TMPA complex (after reduction of nitrite 
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to NO), and prevents NO binding to the Cu(I/II) center thereby suppressing N2O generation.  
Note that NO only weakly binds to Cu(I) complexes.28  
 
Figure 3.5. a) Gas phase IR spectra of headspace N2O solution standards. Inset: calibration curve 
from integration of N2O feature peaks at 2235 and 2212 cm-1; b) gas-phase N2O produced from 
bulk electrolysis of CuTPMA with different levels of nitrite present in the solution phase. 
 
Table 3.2. Effect of nitrite concentration on the current efficiency and gaseous product ratio 
between NO and N2O using CuTPMA mediated nitrite electrochemical reduction. 
 
a) b)
c (NO2-)/mM 
Area of 
μ(N2O)asym 
n(N2O)
/µmol 
N2O current 
efficiency 
NO : N2O 
50 91 2.9 68% 1 : 3.1 
100 54 1.7 41% 1 : 0.5 
200 28 0.9 21% 1 : 0.3 
400 12 0.4 9% 1 : 0.06 
a
) 
b
) 
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Figure 3.6. Cross sectional geometries of a) dual lumen and b) single lumen silicone catheters 
employed in these studies. 
 
As proof-of-concept, such electrochemical NO release chemistry was applied to 
catheters as model biomedical devices to assess the antithrombotic and antimicrobial 
efficacy of this new NO release strategy.  Nitric oxide releasing catheters (cross sectional 
geometries shown in Figure 3.6a) were fabricated by filling the lumen of silicone tubing 
with a solution containing 2 mM Cu(II)TPMA, 0.4 M nitrite, 0.2 M NaCl and 0.5 M MOPS 
buffer (pH 7.2).  Teflon coated Pt and Ag/AgCl wires with 0.039 cm2 (1 cm long) and 
0.079 cm2 (2 cm long) surface areas exposed, respectively, were used as the electrodes to 
conduct electrochemistry within the lumen (see Figure 3.7).   
2.34
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1.27
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Figure 3.7. Schematics of a) single and b) dual lumen electrochemically modulated NO releasing 
catheter configurations examined in this work. 
 
Finite element analysis modeling shows that NO flux out of the catheter mostly 
concentrates around the silicone surface near the working electrode.  Hence, the flux is 
calculated based on the area of the device within a 3 cm long region encompassing the 1 
cm exposed electrode, where >99.8% of the NO resides (see Figure 3.8).   
Similarly, in the catheter configuration, the NO flux can be modulated by applying 
different voltage, and the observed flux, can vary from (0.4–3.0) × 10-10 mol min-1 cm-2 
(Figure 3.9).  Current efficiencies observed are up to 81% towards NO production and 
decrease as the applied potential is made more negative (see Table 3.3).  To test the long-
term stability of NO release, such devices were turned “on” and NO release monitored by 
chemiluminescence for an extended time period.  We found that physiologically relevant 
NO fluxes (> 1.0 × 10-10 mol min-1 cm-2) can be emitted from the catheter for more than 7 
d (Figure 3.10).  
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Figure 3.8. The concentration profile of 7, 5 and 3 cm catheters with 1 cm long active Pt surface; 
concentration profile 100 µm away from catheter surfaces of b) 7 cm c) 5 cm d) 3 cm in length 
along the direction of the white line at different time points; e) integration of concentration of a 7 
cm catheter, with 1, 2 and 3 cm along a line 100 µm away from catheter surface near the exposed 
Pt electrode.   
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Figure 3.9. Modulation of NO flux from a single lumen catheter with 0.0798 cm2 Pt wire.  The 
solution contains 4 mM Cu(II)TPMA, 0.4 M NaNO2, 0.2 M NaCl and 0.5 M MOPS (pH 7.2).  Flux 
calculated based on the 3 cm silicone surface area near the Pt wire.  Potentials are vs. 0.2 M Cl- 
Ag/AgCl. 
 
Table 3.3. Potential applied, NO flux, and NO current efficiency in the single lumen catheter. 
Potential*/V 
NO flux/ 
10-10 mol min-1 cm-2 
Faradaic efficiency 
-0.20 0.4 81% 
-0.25 1.5 80% 
-0.28 2.5 59% 
-0.30 2.9 43% 
-0.32 3.0 31% 
-0.40 3.0 10% 
* Potentials are vs. 0.2 M Cl- Ag/AgCl 
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Figure 3.10. Nitric oxide release from a 7.5 cm long single lumen catheter with 0.080 cm2 Pt wire. 
Inner solution contains 2 mM Cu(II)TPMA, 0.4 M NaNO2, 0.2 M NaCl and 0.5 M MOPS (pH 7.2).  
NO turned “on” (- 0.4 V vs. 0.2 M Cl- Ag/AgCl reference) for 8 d; periods of applied potential 
being turned “off” are also indicated. 
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To test the efficacy of this new NO release concept, 7 h in vivo testing was 
conducted by placing the two single lumen catheters described above in jugular veins of 
anesthetized rabbits with one of the catheters “turned on” (flux ~ 2.0 × 10-10 mol min-1 cm-2) 
and the other “turned-off” (not linked to potentiostat; control).  The degree of surface 
thrombus formation was assessed after removal and by using ImageJ 1.47 software29 to 
determine the amount of clot covering the surface.  The NO releasing catheters consistently 
exhibited reduced thrombosis (p < 0.05, n = 3), with an average of 88 ± 14% reduction in 
thrombus area when compared with the control catheters (Figure 3.11a and SL 1–3 in 
Figure 3.11c).  This reduction in thrombus is not due to any significant temperature change 
for the active NO releasing catheters wired to the potentiostats owing to current flow.  
Indeed, based on simple calculations from Joule’s law, the temperature change within the 
small volume of inner nitrite reservoir solution due to µA levels of current flow would be 
<< 1 °C over a 24 h period.  
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Figure 3.11. Antithrombotic effect of e-chem NO releasing catheters in veins of six rabbits for 7 
h.  Representative pictures of a) single and b) dual lumen catheters after removal from the vein; c) 
thrombosis coverage percentage on the catheters (single lumen: SL 1–3, dual lumen: DL 1–3). 
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In potential clinical practice, any e-chem NO releasing catheter would require at 
least one open lumen to sample blood or infuse agents and a second, closed-off lumen 
dedicated to NO release.  Therefore, it is important to demonstrate that the new e-chem NO 
release methods could be adapted to such a configuration.  This was accomplished using a 
dual lumen catheter (cross sectional geometry shown in Figure 3.6b).  Although such a 
catheter’s asymmetry could cause an uneven distribution of NO at the outer and inner 
surfaces of the lumens, the silicone rubber catheter material has a very high solubility and 
mobility for lipophilic NO,24,25 that provides a reservoir for the e-chem generated NO and 
improves the distribution of the gas.  Indeed, such effect is confirmed by finite element 
analysis simulations, as similar NO concentrations are found near the surfaces of the two 
respective lumens after 30 min of NO generation (see Figure 3.12).  In vivo thrombosis 
experiments with the dual lumen configuration also showed significant reduction of 
thrombosis on NO releasing catheters (p < 0.05, n = 3) with an 83 ± 12% reduction of the 
thrombosis area compared with corresponding controls in the same animals (Figure 3.11b 
and DL 1–3 in Figure 3.11c).  
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Figure 3.12. Distribution of NO concentration around the cross-section of a dual lumen silicone 
catheter (via COMOSOL Multiphysics): a) color map of NO concentration after 30 min of NO 
generation from the electrode surface; b) concentration vs. time at 100 µm from left- and right-side 
of the catheter surface (indicated by pink star in the color map; c) concentration profile on the cut 
line crossing the electrode (yellow dashed line in the color map).  
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To assess the antimicrobial/antibiofilm activity of the new e-chem NO releasing 
catheters, the total adhered viable bacteria on their surfaces after exposure to a flowing 
stream of medium containing the bacteria for 3 d was determined.  The dual lumen catheters 
were tested in a drip flow bioreactor system, which mimics the catheter environment in 
vivo.  The catheter and its peripheral environment (channel surface) were first inoculated 
with high number of bacteria (~108 CFU/channel) and then flushed continuously with fresh 
high nutrient medium (1/10 Laurie Broth) to remove any unattached cells and allow biofilm 
development on surfaces.  Then, E. coli biofilms were grown on the catheter with 
continuous medium flowing (100 mL/h) for 3 d and the NO release was “turned on” for 
only 3 h each day (at flux of 0.6 × 10-10 mol min-1 cm-2).  Even with this low flux of NO 
release and with this release turned on only periodically, bacterial plate counts showed a > 
1000-fold decrease of viable bacteria on the channel surfaces in which the NO releasing 
catheters (n = 5) were placed and a > 100-fold decrease in viable bacteria on the catheter 
surfaces (Figure 3.13 a and b) when compared to controls.  The reduction of biofilm 
formation on the channel walls was so significant that it could easily be observed visually 
(Figure 3.13 c).  It should be noted is that the biofilm data presented here are viable 
bacterial counts on the entire surface of the channel.  
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Figure 3.13. E. coli biofilm developed on dual lumen catheters in a drip flow reactor for 3 d with 
NO turned on for 3 h each day. a) and b): Plate count of the number of viable bacteria attached to 
the catheter surface and channel surface; c) picture shows the dramatic reduction of biofilm 
(indicated by arrow) formed on the channel with NO releasing catheter. 
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One potential concern is the competing reaction of oxygen with reduced 
Cu(I)TPMA.  However, the CV of 1 mM Cu(II)TPMA with nitrite looks similar in air and 
in N2 (Figure S-7), suggesting oxygen reduction has little effect under such conditions.  
The rabbit and biofilm experiments described above all were conducted in the presence of 
oxygen, and the data obtained in these experiments suggest that physiological levels of 
oxygen do not significantly suppress NO production by competing for the Cu(I)TPMA 
sites.  
In the long term, the potential leaching of Cu is also important to consider.  
Literature suggests that Cu(II) ions cannot transport through silicone rubber to any 
significant degree30 and this was confirmed by conducting a 7 d Cu leaching test.  The 
soaking solution contains no copper species above the trace background levels found 
initially within the PBS (see Table 3.4).   
 
Table 3.4. Result of 7 day Cu leaching experiment determined by ICP-OES. 
Sample Intensity Concentration /ppb 
Native PBS 3675 ± 263 10 ± 4 
7 d Soaking of catheters is PBS 3591 ± 293 10 ± 4 
 
3.4 Conclusions 
In summary, electrochemically controlled NO releasing catheters have been 
developed using Cu(II)TPMA mediated nitrite reduction and these devices exhibit 
significant thromboresistance and antiseptic activity.  Longer term (i.e., 3–7 d) in vivo 
experiments to test thromboresistance in freely moving animals are now being planned 
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with such catheters using miniaturized battery powered potentiostats to control the NO 
release fluxes of the devices.  The NO flux control in real-time via such chemistry should 
also enable development of excellent NO(g) sources with different temporal release pattern 
for other biomedical applications, including a new generation of infection-resistant urinary 
catheters and wound healing patches, as well as NO inhalation therapy equipment for 
critically ill patients. 
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CHAPTER 4.  
 
 
IMPROVED IN VIVO PERFORMANCE OF AMPEROMETRIC OXYGEN (PO2) 
SENSING CATHETERS VIA ELECTROCHEMICAL NO 
GENERATION/RELEASE 
 
4.1 Introduction 
Levels of chemical species in blood, including blood gases (pH, partial pressure of 
O2 (PO2), partial pressure of CO2 (PCO2)), electrolytes (Na
+, K+, Ca2+), glucose, and lactate, 
provide invaluable information for the diagnosis and treatment of hospitalized patients.1,2  
Currently, these analytes are intermittently measured in vitro with point-of-care devices 
using blood samples, which provides only periodic information, leaving large gaps in time 
between blood draws.  Continuous monitoring of these species directly within blood 
vessels would greatly improve the quality of health care for critically ill patients.3,4  Indeed, 
the development of intravascular devices that can monitor key physiological species in 
real-time is the “holy grail” in the field of chemical sensors.  Despite extensive efforts over 
several decades, there are currently no sensing devices available that can achieve this goal, 
mostly due to poor biocompatibility of the devices once placed intravascularly (IV) within 
flowing blood.5-7  One of major complications is the formation of clots/thrombus, which 
occurs within hours after blood contact.8  The thrombus can isolate the sensors from the 
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bulk of the blood and cause unreliable analytical results.9  Intravascular thrombus 
formation also has the intrinsic risk to embolize and affect vital organs in the patient.10  
In blood vessels, healthy endothelial cells generate nitric oxide (NO) at the flux 
from (0.5–4.0) × 10-10 mol min-1 cm-2, and one of the functions of NO is to inhibit platelet 
activation/aggregation and prevent clotting at the surface of the endothelial cell layer.11-13  
Inspired by this knowledge, NO release/generation strategies have been adopted for the 
development of more biocompatible IV devices, including electrochemical sensors.14-19  
The traditional NO releasing sensors rely on coatings on the surface of the devices that 
contain NO donors (either by entrapping or covalent attachment) that decompose and 
generate NO spontaneously both in vivo and under storage in buffer solution.20,21  Such 
passive NO release strategies are expensive and have shelf-life issues due to the instability 
of many NO donors utilized to date.  There are also concerns about leaching of NO donors 
and/or byproducts into the blood stream.  These issues have, impeded their adaptation into 
clinical settings.  Strategies based on NO generation from endogenous S-nitrosothiol 
(RSNO) species using immobilized catalysts on the surface of the sensors have also been 
pursued.15  However, the levels of endogenous RSNOs are likely too variable from patient 
to patient to guarantee that enough surface NO can be generated to prevent platelet 
adhesion and clotting for each and every patient.  
Recently, a completely new electrochemical method has been reported to produce 
very controllable NO generation by electrochemical reduction of inorganic nitrite ions 
catalyzed by a copper(II)-ligand complex.22  Not only can the NO generation/release be 
actively controlled “on” and “off”, but also the flux of the NO release from the device 
surface can be readily modulated within the physiologically relevant range, by applying 
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different voltages to an inner working wire electrode.  This “on-demand” NO release 
method is highly desirable for implantable sensors for several reasons, including: 1) during 
the storage, the NO release can be turned “off” and thus the reservoir of NO precursor is 
preserved; 2) sodium nitrite as the NO donor is very stable and inexpensive compared to 
NO donors like diazeniumdiolates and S-nitrosothiols; and 3) the levels of NO release can 
be modulated in vivo, with low levels for most of the time to prevent clotting, and higher 
levels turned on only periodically to better prevent/manage risk of infection.   
In this study, for the first time, the concept of combining electrochemical NO 
generation/release with intravascular chemical sensors to improve their in vivo analytical 
performance is investigated.  Specifically, a dual lumen catheter-type amperometric PO2 
sensor (i.e., one lumen dedicated to electrochemical NO generation and the second lumen 
used for PO2 sensing) is developed to demonstrate this concept.  Such devices can be 
fabricated conveniently using commercial dual lumen silicone rubber catheter tubing 
without any NO releasing/generating coating.  The performance of these sensors is further 
evaluated in rabbit and pig models for up to 21 h, both in veins and in arteries.  The sensors 
were exposed to a wide range of PO2 in vivo from ~20 mmHg to ~480 mmHg, by changing 
ventilator levels of fraction of inspired oxygen (FiO2). 
 
4.2 Experimental Details 
4.2.1 Reagents and Instrumentation   
Sodium nitrite, copper acetate, tris(2-pyridylmethyl)amine (TPMA), sodium 
chloride, sodium bicarbonate, sodium carbonate, potassium chloride, and HEPES buffer 
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were obtained from Sigma-Aldrich (St. Louis, MO).  Teflon® PFA-coated silver (0.127 
mm OD) and platinum wires (0.125 mm OD) are products of A-M Systems (Sequim, WA).  
All solutions were prepared with Milli-Q water (Millipore Corp., Billerica, MA).  Dual-
lumen silicone catheters (7 Fr) were gifted from Cook Medical Inc. (Bloomington, IN).  
Silicone rubber adhesive (RTV-3140) was obtained from Dow Corning (Midland, MI).  
Tanks of gas with varying levels of O2 balanced in N2 were products from Cryogenic Gas 
Inc. (Detroit, MI). 
All electrochemical experiments were performed using CH Instruments multi-
channel potentiostats (1000C, Austin, TX) and a BioStat potentiostat (ESA Biosciences 
Inc., Chelmsford, MA).  Nitric oxide release from the catheters was measured using a 
Sievers Nitric Oxide Analyzer (GE Instruments, Boulder, CO).  Blood gas values from 
blood samples drawn from the test animals were measured using a 700 series blood gas 
analyzer (Radiometer America Inc., Brea, CA). 
4.2.2 Fabrication of Catheter-Type Electrochemical NO Releasing PO2 Sensors   
The procedures used were modified from those reported previously.22,23  A long 
dual lumen catheter (see dimensions in Figure 4.1) was cut to 7 cm in length, and both 
lumens were sealed at one end with silicone rubber adhesive.  The larger lumen was filled 
with a solution containing 4 mM CuTPMA (see Chapter 3 for preparation), 0.4 M NaNO2, 
0.2 M NaCl and 0.5 M HEPES (pH 7.2).  A Teflon® PFA-coated Pt wire (3 cm exposed) 
and a Ag/AgCl wires (5 cm exposed) were inserted into the lumen as working and reference 
electrodes, respectively.  The smaller lumen was filled with 0.15 M KCl in 0.1 M 
bicarbonate/carbonate buffer (pH 10) and a PFA-coated Pt wire (only tip exposed) as well 
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as a Ag/AgCl wire (3 cm exposed) were inserted for oxygen sensing.  The openings of the 
lumens at the proximal end were then sealed (around the wires) with silicone rubber 
adhesives and left cured in water overnight. 
4.2.3 Calibration of PO2 Sensor 
Catheter sensors were immersed in PBS bubbled with different levels of O2 (0%, 
10%, 21%, 100%) at the flow rate of ~500 mL/min.  The PO2 sensing lumen of the catheter 
was polarized at -700 mV in PBS with 0% O2 for 1 h before calibration.  At each level of 
PO2, NO release was switched either from “on” to “off” or from “off” to “on”, by applying 
-400 mV between the working and reference electrodes within the NO generating lumen.  
Note that the two lumens are separate electrochemical cells and the lead wires from each 
lumen are connected to different channels of a multi-channel potentiostat.  To determine 
response times, the sensors were switched between solutions pre-saturated with 0% O2 and 
21% inspired O2.  The response time corresponds to the time needed to reach 90% of the 
steady-state current response after changing the oxygen level. 
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Figure 4.1. Schematic of dual-lumen catheter-type electrochemical NO generating/releasing PO2 
sensor with cross section geometry of catheter. 
 
4.2.4 In Vivo Experiments  
The procedures used were in compliance with the University Committee on the Use 
and Care of Animals as well as federal regulations and were reported elsewhere.15  Briefly, 
New Zealand white rabbits (~3 kg, n = 5) were placed under anesthesia for the 7 h 
experiments.  Two catheter-type PO2 sensors were placed in the jugular veins and 
connected to potentiostats with NO release lumen switched “on” for one of the sensors.  
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No other anticoagulant or antiplatelet agents were administrated to the rabbits during the 
experiments.  The initial FiO2 was 100%.  During the latter part of the experiment, the FiO2 
level was changed to 21% for ~1 h and then switched back to 100%.  Venous blood was 
drawn every 30 min to test for PO2 values using the blood gas analyzer as the reference 
method.  To calibrate the sensors in vivo, the ex vivo data point at the 30 min time point 
after implantation was used as a one-point calibration, with intercept determined by a prior 
benchtop calibration of the oxygen sensing portion of the catheter.  The continuous signal 
from the sensors was compared with the intermittent in vitro blood PO2 values.  The sensors 
with the blood vessels intact were then explanted after systemic heparinization to prevent 
necrotic thrombosis during vessel harvesting. Digital pictures were then taken and the red 
pixels were counted using Image J software to quantify clot area.23,24  
Similar experiments were performed using a porcine model (~50 kg, n = 4) for 21 
h.  The sensors were placed in the femoral and carotid arteries via an open cut-down 
allowing for continuous blood flow past the sensors.  The FiO2 level was maintained at 21% 
and changed periodically to 100% for a 1 h period (ca. every 6 h).  Arterial blood was 
drawn every hour to assess the accuracy of the PO2 values provided by the implanted 
sensors.  Similar to the experiments with rabbits, sensors and vessels were explanted at the 
end of the experiments to allow for quantification of clot burden. 
4.2.5 Signal Processing and Statistics 
The in vivo data from the sensors were recorded every second and averaged every 
30 s to reduce the electronic noise as well as the size of the data set.  A Student’s t-test 
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(two-tail, paired) was used to evaluate the significance of the data sets.  Linear regression 
and R2 were used to evaluate the accuracy and correlation, respectively. 
 
4.3 Results and Discussion 
4.3.1 Rationale for Sensor Design 
A commercial dual-lumen silicone catheter (cross section geometry shown in 
Figure 4.1) was used to fabricate the electrochemical NO releasing PO2 sensors.  Silicone 
rubber is preferred because it is highly permeable towards both the analyte, O2, and the 
anticlotting agent, NO, while impermeable towards the components of the inner reservoir 
ions/species.22,25  One lumen of the catheter is dedicated to O2 sensing, using the cross-
section distal tip of a PFA-coated Pt wire working electrode.  It is held at a cathodic 
potential (-0.7 V vs. Ag/AgCl) where reduction of O2 occurs to yield a steady-state current 
proportional to PO2 levels.  The other lumen is dedicated to NO generation/release and 
contains a reservoir of sodium nitrite (0.4 M) and CuTPMA (4 mM) catalyst.  Note that 
although the cross-section geometry of the dual lumen catheter is not symmetric, it can be 
shown by finite element analysis (via Comsol Multiphysics® software) that the NO 
distribution is symmetrically enhanced around the entire dual lumen catheter assembly 
because of the high diffusivity and solubility of this neutral lipophilic gas molecule in the 
silicone rubber (see Figure 4.2).  
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Figure 4.2. Distribution of NO levels around a dual lumen catheter after 900 s in the presence of 
air from simulation via Comsol Multiphysics®: a) Concentration color map near catheter surface; 
b) concentration of NO outside the catheter along the lines dissecting the catheter at 0°, 45°, 90° 
and 135°, as indicated in a). 
 
4.3.2 Sensor Performance on the Benchtop 
The first study involved assessing the compatibility of the O2 sensing with the 
electrochemical NO generation process.  The design of the sensor facilitates such 
investigation, since the two electrochemical systems reside within the two separate lumens 
of the same catheter device and the NO generation lumen can be easily turned “on” and 
“off” by applying -0.4 V to the Pt working electrode within that lumen.  Thus, the exact 
same sensor can be studied with and without NO release, merely by disconnecting the 
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electrode leads from the NO generating lumen to the potentiostat.  The O2 sensor was found 
to be fully compatible with NO release, as no noticeable amperometric signal changes were 
observed for the O2 sensor when NO generation was switched “on” or “off” at each O2 
level during the calibration (see Figure 4.3).  This is expected as the reaction between NO 
and O2 is second order with respect to NO, implying that the reaction is slow when the 
concentration of NO is low.26  This is true for the catheters under investigation, as they 
generate a relatively low flux of NO, ~1.5 × 10-10 mol min-1 cm-2 (see below).  The high 
solubility of O2 in silicone rubber also sufficiently supplies O2 to the electrode surface even 
if a portion of the O2 does react with NO.  
 
Figure 4.3. Calibration curve of PO2 sensing catheters on the benchtop with NO generation/release 
switched “on” and “off” as indicated. 
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Figure 4.4. Stability of the PO2 sensing catheters over 3 d: a) calibration curve of three sensors on 
different days with continuous NO generation/release; b) summary of the change in sensitivity over 
3 d period for each of the three sensors. 
 
In benchtop studies, the sensors exhibited stable amperometric calibrations during 
storage at 37 °C over 3 d with continuous NO generation/release (Figure 4.4).  The response 
time of the PO2 sensors were ca. 7 min (Figure 4.5), primarily determined by the 
dimensions (e.g., wall thickness) of the dual lumen catheters employed in these studies.  
Although not ideal, this response time is sufficient to be clinically useful, especially 
compared to the current situation where PO2 can only be measured ex-vivo using samples 
of fresh blood.  The response time for standard Clark-type O2 sensor also depends on the 
dimension of the sensor (membrane thickness, distance between the electrode to the 
membrane etc.), but since the membranes can be very thin for ex-vivo sensors, the response 
times of these devices are generally 1 min or so.  This is not possible when the wall of the 
a) 
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catheter is being used as the gas permeable membrane, since wall thickness needs to be 
large enough to provide the catheter mechanical strength to be placed within a blood vessel.   
 
 
Figure 4.5. Typical reversible response of the electrochemical NO generation PO2 sensing catheter 
under investigation. 
 
The NO release of such devices was also examined.  The sensing catheters released 
NO, as measured by chemiluminescence measurements,27 at an average surface flux 
of >1.0 × 10-10 mol min-1 cm-2 (based on the area inserted in blood vessels) for 72 h, which 
is more than sufficient for the short-term proof-of-concept studies reported here (see Figure 
4.6).  The duration of the NO release in these particular devices is limited primarily by the 
small volume of the NO generation reservoir solution containing nitrite ions (~30 µL).  The 
duration of NO generation/release can be readily extended, if necessary, by increasing the 
volume or concentration of sodium nitrite within the reservoir.  It has been shown that 
devices that have a larger reservoir (using longer catheters) can exhibit NO release at 
relevant fluxes for >7 d.22  This provides a simple solution for extending the NO release 
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duration since only a relatively small portion of the device needs to reside within the blood 
vessels.  The surface region of NO release can be controlled by situating the active NO 
generating electrode near the distal end where the catheter is implanted within the blood 
vessel.22  Increasing the concentration of nitrite in the reservoir without changing the 
volume, though effective for longer-term NO release, is limited by the further increase in 
osmotic pressure, which could potentially compromise the stability of the device over 
longer-term use. 
 
Figure 4.6. NO release profile from an electrochemical NO generation/release PO2 sensing catheter.  
NO release was switched “off” at ~ the 8th h to demonstrate the control of the release.  
 
4.3.3  Sensor Performance In Vivo   
The catheter-type PO2 sensors were first studied in rabbit veins over a 7 h period.  
The sensors were purposely challenged with lower venous PO2 levels during the latter 
period of the experiment, by switching the FiO2 from 100% to 21%.  The NO releasing 
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sensors measured the PO2 levels accurately and are able to follow both the decrease of PO2 
at the ~4 h time point and the recovery of PO2 at the ~5.5 h time point (see Figure 4.7a as 
representative example).  In contrast, the signal from the control sensors started to deviate 
negatively during the latter time period of the experiment, and although the sensors 
responded to a decrease of PO2 at ca. the ~4 h mark, the levels measured were not accurate 
(negative deviation from in vitro blood-gas instrument values) and the responses were not 
able to fully recover back when the PO2 was changed to the higher level via increasing the 
FiO2 level.  This was due to the formation of the large blood clots on the control sensor 
(see Figure 4.7b, as example).  Thrombus formation around the catheter surface can create 
a local environment that has lower O2 level because of the consumption of oxygen by 
platelets and other cells within the clot.9  Overall, the NO releasing sensors induce less clot 
formation than the control sensors as measured by imaging the surface of the catheters after 
explantation from the rabbit after 7 h (see Figure 4.7c for data for n = 5 rabbits, p < 0.05).  
Since the PO2 level is different within each individual animal at different time 
points, the accuracy of the sensors was evaluated by quantitating the deviations (Dev) of 
the PO2 values provided by the sensors vs. those provided from the in vitro blood sample 
PO2 measurements at the same time point, assuming the in vitro measured values are 100% 
accurate.  The deviation can be calculated as: 
%Dev = ((PO2 sensor – PO2 reference)/PO2 reference) × 100 
where PO2 sensor is the measured PO2 from catheter-type sensors and PO2 reference is the 
measured PO2 from the blood gas analyzer using the discrete blood samples.  In general, 
the NO releasing sensors showed deviations within ±15% and the differences are not 
significant at each time point (p > 0.2, n = 5 rabbits, Figure 4.7d), while the control sensors 
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exhibited significant negative deviations at time points >4 h after they were implanted 
within veins (p < 0.05, n = 5 rabbits, Figure 4.7d).  It should be noted that venous PO2 
values are typically much lower and encompass a relatively narrow range (25–50 mmHg) 
compared to arterial blood (see below for porcine experiments).  Small changes in the 
venous PO2 values provide information about tissue perfusion.
28  The effective 
functionality of NO releasing PO2 catheter sensors within veins has not been evaluated 
previously.  
For testing the proposed sensors in vivo over longer time periods and over a wider 
range of PO2 levels, the catheter sensors were further implanted within pig arteries for 21 
h.  Again, the FiO2 was varied between 100% and 21% to challenge the sensors with 
different arterial PO2 levels in vivo.  As in the rabbit experiments, the sensors with 
electrochemical NO release followed the changes in PO2 more accurately and reversibly 
while the control sensors without NO generation turned “on” start to exhibit negative 
deviations from in vitro measured PO2 levels after 6 h (Figure 4.8a).  Overall, the NO 
releasing sensors provided more reliable PO2 values for the entire 21 h in vivo experiments 
(n = 4 pigs, p > 0.1 at each time point) while the controls sensors, after 6 h of implantation, 
showed a significant negative deviation of >20% at almost every time point (n = 4 pigs, p 
< 0.05 at each time point except for the 16th h, see Figure 4.8b).  Note that the ability to 
follow active modulation of PO2 in both veins and arteries were demonstrated for the first 
time for these new NO releasing PO2 sensors. 
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Figure 4.7. Performance of electrochemical NO generating/releasing PO2 sensors implanted in 
rabbit veins for 7 h: a) representative response for a NO releasing sensor (black) and a control 
sensor (red) compared with blood draw in vitro test values (blue square); the FiO2 levels were 
changed purposely between 100% to 21% (dash dot) to vary venous PO2; b) representative photo 
illustrating the degree of clot formation on the surface of the control and the NO releasing sensors 
after being explanted; c) average thrombus coverage on NO releasing sensors vs. control sensors 
(n = 5 rabbits, p < 0.05); d) average deviation of the NO releasing sensors (black) and control 
sensors (red) from the reference method (blue).  Error bars indicate standard deviations. 
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Figure 4.8. Performance of electrochemical NO generating/releasing PO2 sensors implanted in pig 
arteries for 21 h: a) representative current response for a NO releasing sensor (black) and a control 
sensor (red) compared with blood draw in vitro test values (reference method, blue square).  Arrows 
indicate where FiO2 changes from 21% to 100%; b) average deviation of the NO release sensors 
(black) and control sensors (red) from the reference method (blue).  Error bars indicate standard 
deviations. 
 
The measurements from both rabbit veins and pig arteries can also be combined 
and compared with the reference method to assess their overall analytical performance in 
vivo (see Figure 4.9).  Data points after the 4 h time point in the rabbits and after the 6 h 
time point in pigs were included in the comparison, since it generally takes time to observe 
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the lowered analytical results for the control sensors (accumulation of clots/thrombus takes 
time).  The NO releasing sensors exhibited good correlation (R2 = 0.97) and accuracy for 
PO2 measurements with an average deviation of  –2 ± 11%, whereas the control sensors 
yielded much poorer correlation (R2 = 0.43) and a deviation of –31± 28%.  Based on the 
periodic blood sample tests as reference method (n = 84), 96% of the measurements from 
NO generating/releasing sensors were within ±20% error, while only 32% of the 
measurements from control sensors were within ±20% error (Figure 4.9).  Linear 
regression was performed on these measurements to obtain slopes for the results from the 
electrochemical PO2 sensors vs. those from the reference in vitro measurement method.  
The electrochemical NO releasing sensors yielded a slope of 0.90 (not shown in Figure 4.9 
for clarity), indicating good overall accuracy.  The control sensors, in contrast, exhibited a 
slope of 0.51, indicating an overall 49% suppression of the signals.  Again, this is most 
likely due to thrombus formation and concomitant entrapped metabolically active cells on 
the surfaces of the control catheters.  
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Figure 4.9. Comparison of measured PO2 from catheter-type sensors in vivo vs. reference method 
from blood samples.  Data contain all the measurements > 4 h time point in rabbit experiments and > 
6 h time point in pig experiments.  Black squares represent results from the NO generating/releasing 
sensors.  The red triangles represent the measurements from the control sensors.  Dash lines and 
solid line indicate ±20% error and 0% error, respectively. 
 
4.4 Conclusions 
Catheter-type amperometric PO2 sensors incorporating a novel electrochemical NO 
generating/release system have been developed.  These NO releasing sensors were 
implanted in both veins and arteries of animal models for up to 21 h and yield less clot 
formation and more accurate analytical results.  This method could provide a general 
strategy for improving the hemocompatibility of a wide variety of blood contacting 
sensors/devices.  Further, owing to the potent antimicrobial properties of NO,29 such 
electrochemical NO generating devices could also greatly lower the risk of infection, which 
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is another major issue with intravascular sensors and other devices, especially when the 
dwelling time is longer than 24 h.  It is envisioned that low level of NO can be used to 
prevent clotting but can be increased for short periods (3 h per day etc.) to better kill 
bacteria.21  This can be readily achieved by the new electrochemical NO release system 
investigated in this study.  Longer-term (7 d) in vivo investigation of the new IV-PO2 sensor 
design in freely-moving animals are currently being planned.  
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CHAPTER 5.  
 
 
DOSAGE EFFECT OF NITRIC OXIDE (NO) AND ITS SYNERGY WITH 
ANTIBIOTIC AGAINST PSEUDOMONAS AERUGINOSA BIOFILM USING 
CONTROLLED RELEASE OF NO FROM AN ELECTROCHEMICAL SYSTEM  
 
5.1 Introduction 
A multitude of chronic infections that arise from different medical situations, such 
as catheter related/induced infections,1 patients with cystic fibrosis,2 or endocarditis,3 etc. 
are caused by Pseudomonas aeruginosa and its biofilms.  Such infections are usually hard 
to cure, not only because this opportunistic pathogen itself often develops resistance 
towards a broad spectrum of antibiotics, but also because of its ability to form biofilms in 
different environments.4,5  To date, treatment of bacterial biofilm-related infections in 
hospitals mostly relies on prolonged exposure to high-dosage antibiotics.6  However, such 
antibiotic treatments alone are usually not successful because these conventional 
antibiotics more effectively target the planktonic cells instead of biofilm.  Furthermore, 
overdose of antibiotics increases the risks of inducing multi-drug resistant strains or 
“superbugs” and other side effects.7  For infections related to indwelling devices (e.g., 
catheters), the biofilms/devices eventually have to be physically removed.  This infection 
challenge calls for new methods with capabilities to quickly eradicate bacterial biofilms 
while still ensuring safety to the host. 
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One proposed effective strategy is to use a small molecule—nitric oxide (NO), 
which is produced endogenously by the human immune system to fight bacterial infection 
during host defense.8  Over the past decade, NO donors themselves as well as NO releasing 
materials have been investigated to either prevent biofilm formation or to remove existing 
biofilms.9-17 However, these NO release strategies often have uncontrolled NO burst 
release, and sometimes result in complications from leaching of the NO donors themselves 
as well as their degradation products, which obscure the true effects of NO.18,19  In addition, 
the effectiveness of short-term steady NO release at physiologically-safe fluxes against 
mature biofilms is not clear, though these fluxes, ranging from (0.5–4.0) × 10-10 mol min-1 
cm-2 (0.5–4.0 flux), are frequently targeted for the development of many NO releasing 
implants, including catheters and stents.20,21  Furthermore, the overall effect of NO at 
different fluxes, including the role of flux on the killing of bacteria and/or dispersal of 
biofilms, needs to be clarified.  If the decrease in biofilm by NO release is mainly due to 
the detachment of live cells from the biofilm, the behavior of theses detached bacteria and 
the risk they pose to the host also needs further investigation.  In addition to the anti-biofilm 
effect of NO, it has recently been found that endogenous NO produced by bacteria can 
protect them against antibiotics.22  These intriguing yet different ways that bacteria interact 
with NO requires more careful study of the dosage effect so that effective control of 
bacteria via NO release can be developed. 
In this study, to evaluate effects of NO at different dosages against bacterial 
biofilms, especially in the physiological flux range that is nontoxic to the host cells, we 
utilize a recently developed, highly controllable electrochemical NO release catheter 
system.16  Using this catheter model we investigate the effect of different fluxes of NO 
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release on mature P. aeruginosa biofilms.  The NO flux from the device surface can be 
controlled readily by applying different voltages across two wire electrodes within a lumen 
of the catheter containing nitrite ions and a copper(II)-complex.  Herein, we demonstrate 
that short-term (3 h) NO release at low physiological flux is able to significantly reduce 
surface-attached mature biofilms.  These levels of NO are also shown to display a synergic 
effect with gentamicin against the bacteria in biofilms.  
 
5.2 Experimental Details 
5.2.1 Catheter Fabrication and NO Release Profile Measurement 
The procedures used were similar to those reported previously.16,23  A single lumen 
silicone tube was cut to 6 cm in length and sealed at one end with silicone rubber adhesive.  
The lumen was filled with a solution containing 4 mM copper(II)-tri(2-
pyridylmethyl)amine, 0.4 M NaNO2, 0.2 M NaCl and 0.5 M HEPES buffer (pH 7.2).  A 
Teflon® PFA-coated Pt wire (3 cm exposed) and a Ag/AgCl wire (5 cm exposed) were 
inserted into the lumen as working and reference electrodes, respectively.  The openings 
of the lumens at the proximal end were then sealed (around the wires) with silicone rubber 
adhesive and left to cure in water overnight (see Figure 5.1).  The NO release profile of the 
catheters was controlled by applying different voltages, and outer surface NO flux was 
measured with a Nitric Oxide Analyzer (Sievers 280i, GE Analytics, Boulder, CO), as 
reported previously.24 
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Figure 5.1. Schematic of the electrochemical NO releasing catheter employed in this study, with 
cutaway view showing the inside configuration of the catheter. 
 
5.2.2 Bacterial Strain and Biofilm Growth 
Pseudomonas aeruginosa PAO1 wild-type strain was obtained from University of 
Washington (UW Genome Sciences, Seattle WA).25  The bacterial strain was maintained 
on Luria Bertani (LB) agar plate and grown in LB broth.  Biofilm was developed in a CDC 
bioreactor (Biosurface Technologies, Bozeman, MT).  Briefly, the electrochemical NO 
releasing catheters were fixed on the holders of CDC bioreactor.  Four mL of overnight 
grown P. aeruginosa wild-type PAO1 culture were inoculated into the CDC bioreactor at 
final concentration about 106 CFU/mL and the CDC bioreactor was left still for 1 h before 
introducing fresh 10% LB media at 100 mL/h using a peristaltic pump and starting the 
magnetic stirrer to generate shear force.  The biofilms were allowed to develop in the 
bioreactor for 7 d at 37 °C, and the catheter pieces were then taken out aseptically from the 
reactor and gently rinsed in sterile PBS to remove any loosely attached bacteria.  The 
catheters were then subject to NO induced bacteria dispersal studies. 
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5.2.3 Microscopic Observation 
The catheters with 7 d grown biofilm were placed in a convertible flow cell 
(CFCAS0003, Stovall Life Science, Greensboro, NC) and the two ends of catheters were 
secured on surface by water-proof glue in order to observe the surface biofilm with a 
microscope.  LB broth (10%) was continuously provided to the flow cell by a peristaltic 
pump at a flow rate of 10 mL/h.  Biofilm dispersal was monitored using a fluorescence 
microscope (Olympus IX71, Center Valley, PA) equipped with Fluorescence Illumination 
System (X-Cite 120, EXFO) and appropriate filter sets.  Image and video were obtained 
using an oil immersion 60× objective lens. 
5.2.4 Dose-Response Studies of NO on 7 Day Biofilms 
The catheters with 7 d biofilms were transferred into 5 mL of PBS in a 15-mL 
corning centrifuge tube.  The wires of the catheters were connected to a multi-channel 
potentiostat (1000C, CH Instrument, Austin, TX), with the platinum wire connected to the 
working electrode lead, and the silver wire to the reference and counter leads.  The NO 
release was then turned “on” for 3 h, by applying the voltages required to achieve the flux 
desired (e.g., -0.22 V for 0.3 flux, -0.23 V for 0.5 flux, -0.26 V for 1.2 flux, -0.275 V for 
1.5 flux, and -0.325 V for 3.0 flux).16  The solution remained static during the experiment.  
After 3 h of NO release, the viable bacterial cells on the catheter surfaces were quantified 
by plate counts.  Briefly, the catheters were taken out of the PBS and the inner filling 
solutions of the catheters were carefully removed using a syringe from the rear side of the 
catheters.  Three cm of the catheter was cut off into a 2 mL of fresh PBS and homogenized 
with the highest speed (TH, OMNI International, Kennesaw, GA) and the homogenized 
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buffer was serially diluted by 10-fold each time with PBS.  Fifty µL of each dilution was 
plated onto LB agar plates and the plates were incubated overnight at 37 °C for colony 
counting.  
The bacteria released to the buffer media during the 3 h NO release experiment 
were also quantified as described above.  The buffer media was homogenized before serial 
dilutions and plate counts.  The catheter samples at each flux level were run in triplicate 
and Student’s t-test was used for statistical analysis. 
5.2.5 Susceptibility Tests of Planktonic Cells towards NO and/or Gentamicin  
A set of NO release catheters were placed in PBS with ~107/mL overnight grown 
bacteria and NO release was turned “on” for 3 h and 24 h without stirring.  The control 
catheters were set up the same way except that the NO release was turned “off”.  The 
bacteria in the PBS were quantified by plate count following the same protocol as described 
above. 
5.2.6 Combination of NO Release with Antibiotic Treatment 
The experimental procedures of this study were similar to that of the dosage 
response study described above.  The biofilm attached catheters were placed in PBS with 
varying concentration of gentamicin (ranging from 0 to 500 µg/mL) and the NO was turned 
“on” at 1.5 flux immediately after being submerged in buffer.  After 3 h treatment, the 
bacteria remaining on the catheter pieces as well as those within the media were quantified 
by plate counting as described above.  
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To further demonstrate the resistance of biofilm-detached cells to gentamicin, the 
catheters with preformed biofilms were also placed in PBS without gentamicin/NO release 
first for 3 h.  Then, the buffers soaking the catheter was further homogenized as described 
above and treated with gentamicin of varied concentrations (0-500 µg/mL) for another 3 h.  
Plate counts of the soaking solutions were again performed as described above.  
 
5.3 Results 
5.3.1 Nitric Oxide Release Profile of the Catheters 
The real time NO release profile of the electrochemical NO release catheters was 
tested via chemiluminescence as described in the Material and Methods section.  As shown 
in Figure 5.2, these catheters exhibit a very steady NO release profile under a given 
constant applied voltage.  Furthermore, the flux of NO from the catheter surface could be 
readily modulated in the range from 0–3.2 flux, simply by applying different voltages to 
the electrode wires.  The ability of such modulation allows biofilms to be grown without 
release of NO from the catheter, while a given amount/flux of NO release can be turned 
“on” at appropriate times thereafter as defined by the study.  
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Figure 5.2. Modulation of surface NO fluxes from an electrochemical NO releasing catheter by 
different applied voltages applied to the metal wire electrodes. 
5.3.2 Dosage Effect Studies of NO on 7 Day Biofilms 
The effect of NO on mature 7 d P. aeruginosa biofilms formed on the catheter 
surface was monitored under microscope in real-time.  The procedures are summarized 
Figure 5.3A.  During the 3 h when the NO was turned “on” at 1.5 flux, the coverage of 
bacterial biofilms became significantly less dense (Figure 5.3B), suggesting that the NO 
release prompted the dispersal of biofilms from the catheter surface.  The biofilms on the 
control device, a catheter containing the same solutions and wires but not connected to the 
potentiostat, remained mostly intact (Figure 5.3C). 
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Figure 5.3. Imaging 7 d P. aeruginosa biofilms with 3 h of NO release at surface flux of 1.5 × 10-10 
mol min-1 cm-2: A) Illustration of the experiment procedure and areas on the catheter that are under 
imaging; B) representative images of NO release catheter and its biofilm at 0 and 3 h; C) 
representative images of control catheter and its biofilm at 0 and 3 h.   
 
As shown in Figure 5.3, 3 h NO release at 1.5 flux resulted in dispersing mature 
biofilms from the catheter surface.  To evaluate the effects of different surface NO flux 
levels on mature biofilms, catheters with 7 d preformed P. aeruginosa biofilms grown onto 
the catheter surfaces were transferred into fresh PBS before different NO fluxes were 
turned “on” electrochemically.  After NO was released for 3 h at given fluxes, both the 
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bacteria on the catheter surfaces (in biofilms) and those detached/dispersed into the PBS 
media were quantified by viable plate counts.  On the catheter surfaces, NO release at 0.3 
flux for 3 h reduced the attached bacteria by 86%, and the effects became stronger as the 
NO flux was increased, reaching a 3 log reduction with NO flux > 1.5 flux (see Figure 5.4 
and Table 5.1).  During 3 h experiments without NO release, a small portion of the bacteria 
in the biofilms detached spontaneously into the media (about 3.5%, see Table 5.1).  With 
NO release at 0.3 flux, the number of viable bacteria in the media increased by 88% on 
average as compared to the control, revealing a significant biofilm dispersal effect of the 
electrochemically released NO.  Overall, the number of total viable cells decreases both on 
catheter surfaces and in media as the NO flux increases (Table 5.1), indicating a 
simultaneous dispersing and killing effect with increased NO flux. 
 
Figure 5.4. Dosage response of 3 h NO release on 7 d P. aeruginosa biofilms. Viable bacteria 
counts A) on the surface of catheters and B) within the media after NO release for 3 h in the PBS. 
Asterisk denotes statistical significance at each flux compared with 0 flux (n.s.: p > 0.05, * p < 0.05, 
** p < 0.01). 
 
 111 
 
Table 5.1. Effect of NO flux on dispersing and killing of mature 7 d P. aeruginosa biofilms. 
NO flux 
/10-10 mol min-1 cm-2 
0 0.3 0.5 1.5 3.0 
Attached viable cells 96.5% 13.4% 0.8% 0.1% 0.1% 
Detached viable cells 3.5% 6.6% 2.2% 1.4% 0.5% 
Total viable cells 100.0% 20.0% 2.9% 1.6% 0.5% 
 
5.3.3 Killing Kinetic Studies on Biofilm and Planktonic Cells 
Since NO is effective in reducing bacteria in mature biofilms on the catheter surface 
after such a short period of exposure (3 h), we studied the kinetics of killing with 1.5 flux 
of NO.  As can be seen in Figure 5.5 (left two columns), approximately a 2 log unit decrease 
in the number of surface viable bacteria was observed after 3 h and an additional 1 log 
decrease was obtained after 24 h of NO release treatment. 
 
Figure 5.5. Effect of 3 h and 24 h NO release (1.5 flux unit) treatment towards P. aeruginosa 
biofilms (7 d) on the catheters and its planktonic counterparts in the PBS.  Asterisk denotes 
statistical significance (n.s.: p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001). 
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Such NO killing kinetics studies were also performed on the planktonic cells in 
PBS.  After 3 h of NO release, no obvious killing was observed, wherease 24 h of NO 
release killed 54% of bacteria (Figure 5.5, right two columns).  The much less killing effect 
of NO towards planktonic cells is likely because the level of NO is the highest at the surface 
of the catheter, and diminishes rapidly within the bulk solution due to reaction of NO with 
oxygen and components of bacteria (proteins, etc.).26-28 
5.3.4 Synergistic Effect of NO Release with Antibiotic 
Since NO is less effective in killing bacterial cells in the media (as shown above), 
we next explored if more effective killing could be achieved by combining the NO release 
with conventional antibiotic treatment.  We used gentamicin in this study, as this 
aminoglycoside has been previously employed in the treatment of gram-negative bacteria 
infections, including P. aeruginosa.29  The catheters with mature P. aeruginosa biofilms 
were placed in PBS containing different concentrations of gentamicin (ranging from 0-500 
µg/mL), and NO release was controlled electrochemically.  Without NO release (control), 
bacteria in the biofilms were highly resistant towards gentamicin at concentrations up to 
500 µg/mL, with less than a 1 log reduction (see Figure 5.6A).  As a control, the P. 
aeruginosa planktonic cells were completely eradicated (> 7 log reduction) in 3 h at 500 
µg/mL (Figure 5.6B), confirming previous studies in the literature30 that cells in biofilms 
are much less susceptible to antibiotic treatment.  However, a significant synergistic effect 
was observed when NO release was combined with gentamicin.  Release of NO at 1.5 flux, 
together with 25 µg/mL gentamicin in the buffer resulted in a combined ca. 3 log reduction 
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of the surface viable cells.  The effect was enhanced further to > 3 log reduction with 100 
µg/mL gentamicin and close to a 5 log reduction with 500 µg/mL gentmicin (Figure 5.6A).  
 
Figure 5.6. Combination of NO release with different concentrations of gentamicin against 7 d P. 
aeruginosa biofilms.  A) Surface attached bacterial biofilm after 3 h treatment of gentamicin 
(gentamicin), and gentamicin with simultaneous NO release at 1.5 flux (gentamicin/NO); B) 
biofilm-detached/released bacteria vs. planktonic suspension control in the media with different 
treatments: 3 h exposure to different concentration of gentamicin (gentamicin); 3 h NO release at 
1.5 flux in the presence of varied concentration of gentamicin (gentamicin/NO). 
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The synergistic effect between NO and genamicin was also investigated towards 
the cells detached/released into the media from the biofilms.  Without NO release, the 
detached/released cells in the media were highly resistant to gentamicin over the  entire 
concentration range investigated (< 0.5 log reduction with up to 500 µg/mL gentamicin 
treatment) (Figure 5.6B, solid line with square).  Similar resistance was also observed even 
when the detached/released cells were homogenized first before the antibiotic treatment 
(data not shown), which is in contrast to the high suspectibility of the wild-type planktonic 
cells in the media (Figure 5.6B, dash line with solid circle).  However, this resistance was 
significantly reduced when gentamicin was combined with simultaneous NO release, with 
almost a 2 log reduction of the viable cells when 25 µg/mL of gentamicin was combined 
with a 1.5 flux of NO. (Figure 5.6B)  The reduction was further enhanced to > 3 log unit 
when 100 and 500 µg/mL of gentamicin was combined with NO at the same flux, 
indicating a significant synergistic effect of gentamicin and NO (Figure 5.6B, dotted line 
with triangle).  
Release of NO also enhances the killing efficacy of gentamicin against planktonic 
suspension of P. aeruginosa, leading to an additional 1 log reduction of the cells at 25 and 
100 µg/mL of gentamicin when NO was simultaneously released at 1.5 flux (Figure 5.6B, 
solid line with triangle). 
5.4 Discussion 
5.4.1 Killing Effect of NO on Biofilms on the Surface vs. Planktonic Cells in the Media 
For the biofilms attached to the catheter surface, it was found that the higher the 
flux of NO release, the less viable bacteria remained on the surface (Figure 5.4).  The wild-
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type P. aeruginosa expresses NO reductase (nor) in the biofilms, which is believed to 
prevent the accumulation of “toxic” NO during denitrification.31  In this study, we found 
that the exogenous NO release in the physiological range is still effective in killing such 
bacteria within the biofilms.  On the other hand, the planktonic cells in the media (both the 
planktonic suspension as well as the cells detached/released by the biofilms) exhibits less 
susceptibility to the NO release (Figure 5.4 and Figure 5.5).  Overall, the NO release at 0.3 
to 3.0 flux units can effectively decrease the total viable bacteria on surfaces and bacteria 
detached in the surrounding solution and its killing effect is positively correlated with NO 
dosage (Table 5.1).  
5.4.2 Modeling of the Transport of NO 
The reduced killing efficacy displayed by the similar fluxes of NO against 
planktonic cells in the media vs. cells in the biofilms is quite interesting.  There are several 
potential explanations for this.  First, because NO is released constantly from the surface 
of the catheter, the concentration of NO should be highest immediately adjacent to the 
surface.  This is where the bacterial cells are attached and the level of NO decreases as 
distance from the catheter increases.  Secondly, the lower diffusivity of gases in the biofilm 
matrix might lead to the further accumulation of NO locally near the catheter’s surface.5  
Further, deep inside the biofilms, the environment is usually near anoxic; this means that 
loss of NO by reaction with O2 will be reduced, resulting in a higher effective NO 
concentration than within an ambient air environment.  To investigate all these effects, a 
1-D axial symmetry model was set up and the diffusion equations were solved by numeric 
simulation under each condition (Figure 5.7A).  Indeed, all these hypotheses were verified 
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by the simulation.  Under all conditions investigated, NO concentration is highest at the 
catheter surface and decreases as the distance to the catheter surface increases (Figure 
5.7B).  When the diffusivity was set to 60% of the that in water in ambient air environment 
to represent the diffusion in biofilms 5, the accumulation effect is observed, with increases 
of 22% and 9% in the NO concentration at the catheter surface and 100 µm away from the 
catheter surface, respectively (Figure 5.7B).  When the O2 environment was switched from 
ambient to anoxic, a 1.7× increase in NO concentration is predicted on the catheter surface 
(Figure 5.7B).   
On the other hand, under ambient air, NO concentration at 1 mm away from the 
catheter is only ~5% of that on the catheter surface after 5 min of NO release.  This means 
bacteria in the bulk of the media are exposed to far less effective NO and, therefore, are 
not susceptible towards the NO killing effect.  It should be noted that this model only 
considers the diffusion and reaction of NO with O2 and neglects the complications from 
uptake of NO by the bacteria as well as other reactions.  However, these complications 
should not change the qualitative effects predicted by the model. 
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Figure 5.7. Effect of O2 environment and diffusivity of NO on the NO concentration profile near 
the catheter surface via simulation. A) Illustration of the 1-D axial symmetry model. Point O 
represents axial symmetric line for the catheter; Point A is catheter surface where constant NO at 
1.5 flux is released; Point B represents semi-infinite boundary condition where concentration of 
NO is 0.  R is the radius of the catheter. B) NO concentration profile after NO release is “on” for 5 
min: normal diffusivity (diffusivity in water) with ambient air (solid line); 60% diffusivity (slower 
diffusion in biofilms) with ambient air (short-dotted line) and 60% diffusivity in anoxic 
environment (deep inside biofilms, dashed line). 
 
5.4.3 Synergistic Treatment Effect of NO Release and Gentamicin 
The synergistic effect between NO and biocides has previously been shown in the 
treatment of gram-positive and gram-negative planktonic bacteria32 as well as multi-
species biofilms from water distribution systems.10  Controversially, endogenous NO 
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produced by bacteria also has been reported to increase the resistance of bacteria toward 
broad-spectrum of antibiotics.22  In our study, the synergy between the NO and gentamicin 
treatment were observed in killing bacterial cells in biofilms, biofilm detached/released 
cells, as well as planktonic cells (Figure 5.6).  Several mechanisms have been proposed 
regarding the aminoglycoside resistance in P. aeruginosa, including enzymatic 
modification (phosphorylation, acetylation, adenylation, etc.) of the aminoglycoside 
species,33 changes in the membrane permeability,34 and altered ribosome binding sites.35  
Evidence shows that NO can upregulate genes involved in energy metabolism.36  Therefore, 
we postulate that NO increases the permeability of the membrane by increasing the 
metabolism, thereby accelerating the energy-dependent process of gentamicin uptake.37  
Detailed studies are warranted on how NO might modify the genes related to antibiotic-
resistance and their expression, to better understand such a mechanism. 
As indicated above, P. aeruginosa biofilms are highly resistant toward antibiotic 
treatment.  What is surprising is that the cells detached/released from the biofilm have 
enhanced capacity for resisting gentamicin, regardless of whether they are aggregated 
together or suspended as single cells.  This is in contrast to their planktonic counterparts.  
Since bacteria in biofilm are highly heterogeneous in genetics,38 it is very likely that the 
detached/released cells have genetically mutated and become antibiotic resistant.  Further 
investigation is needed to better understand and verify such a mechanism.  
The results from this study also suggest that for the biofilm associated infections in 
hospitals, the challenge might not be just the biofilms themselves, which are notoriously 
hard to remove.  The highly resistant cells released from the biofilms should also receive 
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attention, as these motile cells may circulate and grow inside the body to cause secondary 
or systemic infections while escaping from the traditional antibiotic treatments. 
The fact that a very low amount of NO release is effective in removing the biofilms 
over a very short time period demonstrates a potent way to resolve the significant problem 
of biofilms that partially cause the large number of catheter associated infections that kills 
more than 20,000 patients in hospitals each year in the U.S. alone.39  Indeed, the use of 
multi-lumen catheter devices in which one lumen is dedicated to the electrochemical NO 
release system utilized in these studies should be quite useful, even if the devices are turned 
“on” for NO release for only a few hours each day.  For cystic fibrosis patients, where P. 
aeruginosa biofilms pose huge challenge, NO released from acidified nitrite has already 
been shown to be effective in reducing P. aeruginosa biofilms within the airways and lungs 
of patients afflicted with this disease.40  However, acidified nitrite also produces nitrogen 
dioxide (NO2), which is toxic towards both the host and the pathogens.  In this case, 
inhalation of low dose NO from an electrochemical gas phase NO generation system should 
be an attractive alternative to treat this disease as the NO can be produced on demand and 
at a rate of release that can be carefully controlled electrochemically, potentially enabling 
in-home low-dose NO inhalation therapy for such patients.  
 
5.5 Conclusions 
Electrochemical NO release from a catheter tubing surface has been utilized to 
study NO’s effect on mature P. aeruginosa biofilms.  Dosage response studies revealed 
that a significant killing effect of NO at physiological fluxes (>0.5 × 10-10 mol min-1 cm-2) 
occurs, reducing mature P. aeruginosa biofilms by more than 2 log units.  In the absence 
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of NO, both the bacteria in the biofilms and those detached/released from the biofilms were 
highly resistant towards antibiotic treatment, but became more susceptible when exposed 
to NO.  Synergy between NO and gentamicin was found against biofilm and detached cells.  
Up to a 6 log unit reduction of biofilms bacteria on the catheter surface was observed upon 
the combined exposure of the biofilms to a 1.5 flux of NO for 3 h and 500 µg/mL 
gentamicin.  Such a combination of NO release with existing antibiotics might provide a 
potent treatment for infections caused by resistant bacteria.  This study provides additional 
insight into the potential treatment of biofilm-related infections using various NO therapies 
alone or in combination with gentamicin.  
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CHAPTER 6.  
 
 
EXPERIMENTAL AND SIMULATION STUDIES OF TRANSPORT OF NO 
THROUGH BIOMEDICAL GRADE POLYMERS AND ITS EFFECT ON LOCAL 
NO FLUX DISTRIBUTION ON MEDICAL DEVICES 
 
6.1 Introduction 
Biocompatibility is central to the design and performance of medical devices.  The 
issues of biocompatibility include clot formation on blood contacting devices,1 foreign 
body response on subcutaneous implants,2 biofilm formation and microbial infections on 
all types of invasive devices.3  One promising means to combat all of these issues with a 
single agent is to employ nitric oxide (NO), an endogenous molecule with potent 
antithrombotic, antimicrobial and immune suppressing properties.4-7  However, because 
NO is a gas molecule and is relatively reactive, the use of NO donors together with proper 
release methods are necessary to deliver NO locally to be effective.8  Nitric oxide donors 
can either be covalently attached to or non-covalently incorporated within polymers,9,10 
and such polymers are then used either as coatings for devices, including intravascular 
sensors, or as the bulk material of the devices (e.g., catheters, intravascular sensors and 
stents).11-13  
Two types of biomedical polymers, silicone rubber14-17 and polyurethanes,18-20 are 
extensively used in creating NO releasing materials because of their innate compatibility 
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with NO release chemistry, appropriate mechanical properties and stability in vivo.21  
However, the transport properties of such polymers with respect to NO diffusion rates, 
partition coefficients, etc. have been less studied.  Such transport properties can 
significantly affect the observed NO release profile, including surface flux of NO, 
longevity of release, duration to reach steady state release, as well as the NO release 
distribution of NO around the surface of actual devices.  Such transport properties, once 
known, can help predict the NO release profile and NO distribution around the devices, 
and therefore help guide the optimal design/configuration of devices for biomedical 
medical applications.  
Mowery et al. did examine the transport of NO in polymers and obtained apparent 
diffusion coefficients for PVC, silicone rubber and two aliphatic polyether polyurethanes.22  
Although useful in predicting the average flux at steady-state, transient processes, transport 
processes involving chemical reactions, and local flux distribution cannot be accurately 
described by using apparent diffusion coefficients alone.  This is because this coefficient 
includes the mixed processes of both diffusion and partitioning.  Polymers with same 
apparent diffusion coefficient can display very different NO release profiles and 
distributions under non-steady-state conditions.  Moreover, the transport properties of NO 
in newly developed polyurethanes that have been shown to exhibit improved stability and 
biocompatibility in vivo have not been reported.23 
To better understand the time-dependent NO transport and release processes in 
polyurethanes and to improve the design of NO releasing scaffolds and devices, in this 
study, the transport properties of different polyurethanes, including classic aliphatic, 
aromatic polyether polyurethanes, as well as newly developed silicone and polycarbonate 
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containing polyurethanes are examined.  The true diffusion coefficients of NO in these 
polymers are studied separately from the partition process.  Finally, finite element analysis 
is used to simulate the effects of diffusion and partitioning on the NO release profile as 
well as distribution of NO at the outside surface of multi-lumen catheter, and the simulation 
results are compared with experimental data.  
 
6.2 Theory 
6.2.1 Gas Transport in Polymers: Diffusion and Solution 
Transport of gas through polymers can be described by two different processes—
diffusion and solution.  Solution is the process of gas partitioning between the polymer 
phase and the gas or liquid phase, and therefore the term partition and solution are used 
interchangeably in this chapter.  Figure 6.1 summarizes a general 1-D model for NO 
permeation from one stream (upstream) into another stream (downstream) through a 
polymer layer, which describe the transport process in the diffusion experiments conducted 
in this study, as well as NO release process from a NO reservoir inside a polymeric 
membrane, e.g., electrochemical (e-chem) NO release system. 
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Figure 6.1. Schematic for NO permeation through polymer film/wall with thickness of L. 
 
Suppose gas molecules dissolved in a solution (Domain I) with bulk concentration 
C* need to permeate through a polymeric membrane (Domain II) and enter the downstream 
solution on the other side of the membrane (Domain III).  First, the dissolved gas in Domain 
I needs to be transported to close proximity to the polymer/solution interface (Boundary I) 
by diffusion (diffusion coefficient D) and convection.  Second, the gas close to the interface 
(Boundary I) must partition between the polymer and solution phases.  This partitioning 
process can be viewed as two elementary steps: adsorption (transfer from solution into 
polymer, with a first order heterogeneous rate constant ka); and desorption (transfer from 
polymer into solution, with a first order heterogeneous rate constant kd).  The ratio of ka/kd 
determines the partition coefficient K between the two phases.  In the third step, the gas 
molecules that partition into the polymer domain (Domain II) are transported to the other 
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interface of the membrane (x = L) by diffusion (diffusion coefficient ?̅?; the bar denotes the 
membrane phase).  The fourth step, again, involves partitioning of gas molecules between 
polymer/solution interface (Boundary II) with the same ka and kd as in the second step.  
Finally, the gas molecules that has entered the receiving solution (Domain III) will be 
transported away.  The driving force for all these processes is the chemical potential 
gradient, or equivalently, the concentration gradient in this study.  
Several assumptions are made to simplify the mathematical model for the diffusion 
process shown in Figure 6.1.  First, we assume that all the diffusion processes are Fickian.  
That is, the magnitude of flux is proportional to the concentration gradient, and the 
diffusion coefficient is concentration independent.  This assumption is a valid as the gas 
molecule are small and the concentration of gas in the experiment is low, ensuring no 
significant change of the polymer, structurally or dynamically, by the presence of the 
diffusing gas molecules (i.e., no swelling or plasticization).  Secondly, the membrane is 
isotropic and homogeneous.  This should be macroscopically true for the polymers under 
study.  Based on these assumptions, diffusion equations in the three domains coupled by 
partitioning in 1-D as well as the corresponding initial values and boundary conditions are 
shown below: 
 
Domain I  
 𝜕𝐶(𝑥, 𝑡)
𝜕𝑡
= 𝐷
𝜕2𝐶(𝑥, 𝑡)
𝜕2𝑥
 (1) 
 𝐶(−∞, 𝑡) = 𝐶(𝑥, 0) = 𝐶∗ (2) 
 𝐽(0, 𝑡) = 𝑘𝑑𝐶̅(0, 𝑡) − 𝑘𝑎𝐶(0, 𝑡) = 𝑘𝑑[𝐶̅(0, 𝑡) − 𝐾𝐶(0, 𝑡)] (3) 
Domain II:  
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 𝜕𝐶̅(𝑥, 𝑡)
𝜕𝑡
= ?̅?
𝜕2𝐶̅(𝑥, 𝑡)
𝜕2𝑥
 (4) 
 𝐽(̅0, 𝑡) = −𝐽(0, 𝑡) = 𝑘𝑑[𝐾𝐶(0, 𝑡) − 𝐶̅(0, 𝑡)] (5) 
 𝐽(̅𝐿, 𝑡) = [𝑘𝑎𝐶(𝐿, 𝑡) − 𝑘𝑑𝐶̅(𝐿, 𝑡)] = 𝑘𝑑[𝐾𝐶(𝐿, 𝑡) − 𝐶̅(𝐿, 𝑡)] (6) 
 𝐶(𝑥, 0) = 0 (7) 
Domain III:  
 𝜕𝐶(𝑥, 𝑡)
𝜕𝑡
= 𝐷
𝜕2𝐶(𝑥, 𝑡)
𝜕2𝑥
 (8) 
 𝐽(𝐿, 𝑡) = −𝐽(̅𝐿, 𝑡) = 𝑘𝑑[𝐶̅(𝐿, 𝑡) − 𝐾𝐶(𝐿, 𝑡)] (9) 
 𝐶(+∞, 𝑡) = 𝐶(𝑥, 0) = 0 (10) 
 
Equations (1) (4) (7) are diffusion equations in the different domains, and the other 
equations are initial values and boundary conditions.  Equations (3) (5) and Eqs (6) (9) 
couple diffusion in Domains I, II and in Domains II, III, respectively, by enforcing a 
continuous flux across the boundaries.   
For the diffusion experiment, assuming stirring provides sufficient mixing in 
Domain I, the concentration of NO in solution can be treated as homogeneous during the 
experiment.  A large amount of solution volume in Domain I as compare to the membrane 
volume (Domain II) ensures that concentration of NO in Domain I remains essentially 
unchanged in the time scale of a typical diffusion experiment.  The homogeneity and time 
invariance of NO concentration simplifies Eqs (1) and (2) to: 
 𝐶(𝑥, 𝑡) = 𝐶∗, for x < 0 , (11) 
Assuming fast partition equilibrium at the interface, the Eqs (3) and (5) can be 
reduced to: 
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 𝐶̅(0, 𝑡) = 𝐾𝐶(0, 𝑡) = 𝐾𝐶∗ (12) 
Similarly, because NO in the downstream (Domain III) is rapidly pumped into the 
detector for measuring the rate of NO transport, the concentration of NO in Domain III is 
essentially zero at all times. Eqs (8) and (10) are therefore reduced to: 
 𝐶(𝑥, 𝑡) = 0 , for x > L (13) 
And by analogy for fast equilibria, Eqs (6) and (9) become: 
 𝐶̅(𝐿, 𝑡) = 𝐾𝐶(𝐿, 𝑡) = 0 (14) 
Under these conditions, the complicated coupled diffusion in three domains is 
simplified into the diffusion process in Domain II alone, with governing equation Eq (4) 
and boundary conditions provided by Eqs (12) and (14) and initial value, Eq (7). 
Such diffusion equations can be solved exactly, and integrating the flux at x=L over 
time yields: 
 
𝑄(𝐿, 𝑡) =
𝐷𝐾𝐶∗
𝐿
(𝑡 −
𝐿2
6?̅?
+
2𝐿2
𝜋2𝐷
∑
(−1)𝑛+1
𝑛2
exp(−
?̅?𝑛2𝜋2t
𝐿2
))
∞
𝑛=1
 (15) 
where 𝑄(𝐿, 𝑡) denotes the amount of gas that penetrates the membrane per unit area at time 
t.  When t -> ∞, the exponential term is dropped: 
 
𝑄(𝐿, 𝑡) =
𝐷𝐾𝐶∗
𝐿
(𝑡 −
𝐿2
6?̅?
) (16) 
Therefore, plot of the amount of permeated gas versus time will approach a linear 
asymptote as t-> ∞, with an intercept at the x axis: 
 
𝜏 =
𝐿2
6?̅?
 (17) 
τ is defined as the time lag.  Once the membrane thickness L and time lag τ are obtained, 
the diffusion coefficient can be calculated from Eq (17). 
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First derivative of Eq (15) gives: 
  
 
𝐽(𝐿, 𝑡) =
𝐷𝐾𝐶∗
𝐿
+
2𝐷𝐾𝐶∗
𝐿
∑(−1)𝑛 exp(−
?̅?𝑛2𝜋2t
𝐿2
)
∞
𝑛=1
 (18) 
The first term of Eq (18) corresponds to the steady-state portion of the flux, whereas the 
second term corresponds to the transient portion of the flux.  As t -> ∞, the flux reaches 
steady-state: 
 
𝐽(𝐿, 𝑡) =
𝐷𝐾𝐶∗
𝐿
 (19) 
From the steady-state flux, 𝐷𝐾 can be obtained.  Together with the 𝐷 obtained 
from the transient time lag, the partition coefficient K can also be determined.  This forms 
the basis for measurement of both the diffusion coefficients and partition coefficients of 
NO in this study for a variety of biomedical polymers. 
Under other conditions, for example, electrochemical NO generation from catheters 
(as reported in Chapters 2 and 3, see Figures 2.1 and 3.7 for the schematics), the assumption 
of effective stirring in Domain I is no longer valid and a diffusion layer will exist within 
the inner source solution phase.  Therefore, diffusion equations in Domain I and II need to 
be coupled together.  Distribution of NO around an actual catheter surface is also of interest 
during the application of these type of devices.  Under this circumstance, however, the 1-
D model is not sufficient to describe the distribution process.  This complicated case can 
be solved in higher dimension numerically using finite element analysis, which is described 
within the next section.  
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6.3 Experimental and Simulation Methods 
6.3.1 Materials and Instrument 
Sodium nitrite (99.99%), potassium iodide, and sulfuric acid were purchased from 
Sigma-Aldrich (St. Louis, MO) and used as received.  All the solutions were prepared with 
deionized water from a Milli-Q system (18 MΩ cm-1; Millipore Corp., Billerica, MA). 
Carbosil 20 80A and Bionate 80A were from DSM (Heerlen 
Netherlands), while Elast-Eon 5-325 80A (E5-325) was from AorTech International plc 
(Weybridge, UK).  Tecoflex SG-80A and Pellethane 80AE were gifts from Lubrizol 
(Cleveland, Ohio).  Silicone rubber sealant (RTV-3140) was a product of Dow Corning 
(Midland, MI).  
6.3.2 Membrane Preparation 
All the polyurethane films were prepared by casting a 10 wt% solution of the polymer in 
THF in a 6 cm diameter glass O-ring on a glass slide.  The slide was left to dry in a fume 
hood for 24 h and then placed under vacuum for further drying for another 4 h period.  
Silicone rubber films were prepared by casting a suspension of RTV sealant in THF within 
a 6 cm Teflon O-ring on a Teflon slide with 48 h drying under ambient conditions.  
Selective chemical properties of all the polymers used in this study are listed in Table 6.1. 
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Table 6.1. Chemical properties of silicone and polyurethanes used in this study. 
Polymer 
Name 
Description 
PD
MS
/% 
Soft Segment 
Hard 
Segment 
Hard 
Segme
nt/% 
Density
/(g 
mL-1) 
Silicone  
Silicone 
rubber 
100 PDMS - - 1.05 
Elast-Eon 
5-325 
Silicone 
Polyether 
Polyurethane 
66 
PDMS:PHMG 
(98:2) 24 
MDI:BDO 32.5 24 1.08 
Tecoflex 
SG-80A 
Polyether 
Polyurethane 
0 PTMG HMDI:BDO 40 25 1.04 
Carbosil 
20-80A 
Silicone 
Polycarbonate 
Polyurethane 
20 
PHEC: PDMS 
(66:34) 
MDI:BDO 
40-45 
26 
1.16 
Pellethane 
80AE 
Polyether 
Polyurethane 
0 PTMG MDI:BDO 45 27 1.11 
Bionate 
80A 
Polycarbonate 
Polyurethane 
0 PHEC26 MDI:BDO 35 26 1.19 
PDMS = poly(dimethylsiloxane); PHMG = poly(hexamethylene oxide); PTMG = 
poly(tetramethylene oxide); PHEC = poly(1,6-hexyl 1,2-ethyl carbonate); MDI = 4,4′-methylene-
bis(phenyl isocyanate); HMDI = 4,4′-methylene-bis(cyclohexyl isocyanate); BDO = 1,4-
butanediol. 
6.3.3 NO Transport Measurements  
In a diffusion cell, a membrane was clamped in between the two parts of the cell 
(see Figure 6.2 for the experimental setup).  Solutions of 0.1 M H2SO4 and 5% KI were 
pre-purged with N2 for 20 min to remove O2.  A 3.5 mL aliquot of each solution was then 
added to the left side of the diffusion cell.  Afterwards, each side of the cell was purged 
thoroughly with N2 again for another 20 min to eliminate O2.  The solution on the left side 
was then vigorously stirred throughout the entire time of the experiment.  Then, the time 
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was recorded when a 50 µL aliquot of a NaNO2 standard solution (5 mM) was injected into 
the 7 mL solution on the left side of the cell.  The NO flux was measured in real time with 
chemiluminescence using a nitric oxide analyzer (NOA) (Sievers 280i, GE Analytics, 
Boulder CO) until the steady-state flux was reached on the right side of the cell. 
Alternatively, 0.1 M H2SO4 and 5% freshly made ascorbic acid can also be used to 
generate NO from nitrite solutions, when I2 adsorption was found to be significant on the 
polymer surface.  
 
Figure 6.2. Schematic for the diffusion experiment performed in this study.  The polymeric 
membrane is clamped between two parts of the diffusion cells.  The left cell is filled with KI and 
H2SO4 to generate NO when nitrite is added.  The right cell is connected directly to nitric oxide 
analyzer (NOA). 
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6.3.4 Fabrication of Electrochemical NO Releasing Silicone and PU Catheters 
Standard silicone tubing was purchase from VWR.  PU tubing was prepared by dip 
coating of a 15 wt% of SG80A in THF on a 2.0 mm diameter straight stainless steel mandrel 
(McMaster-Carr, IL).  The tubing obtained had a ~0.3 mm wall thickness and were cut off 
for the fabrication of the electrochemical NO releasing catheters.  The procedures were 
similar manner as previously reported (see Experimental Details in Chapter 3).28,29  
6.3.5 Measurement of Asymmetric Release by Agar Immobilization 
An electrochemical NO releasing catheter was mounted on a glass slide with tape.  
A hot 1% agar was poured onto the glass slide so that the agar incorporated the catheter 
when cold.  The agar was further cut so that the cross sectional geometry was rectangular 
with catheter in the center.  The NO release was then turned on, and nitrite content at each 
side of the catheter was measured by measuring the nitrite content using 
chemiluminescence.  Briefly, the agar sample was dissolved in DI water, and aliquots of 
the solution was injected into a cell containing degassed 5% KI and 0.1 M H2SO4 solution 
to convert nitrite to NO. The cell was connected to a nitric oxide analyzer for NO 
measurement via chemiluminescence.   
6.3.6 Simulation Methods 
Finite element analysis via Comsol Multiphysics (5.0b) was used to simulate the 
effect of partition coefficient and diffusion coefficient on the NO release profiles when 
using single lumen catheters and the NO distribution when employing multi-lumen 
catheters. 
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Figure 6.3. Geometry and meshing for (A) single lumen, (B) commercial dual lumen, and (C) 
proposed symmetric triple lumen catheter used in the finite element analysis.  
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Table 6.2. Parameters used in finite element analysis. 
Symbol Description Value 
D Diffusion coefficient for NO in water 2.21 × 10-5 cm²·s-1 
N Flux of NO at electrode surface 6.4 × 10-9 mol cm-²·min-1 
K Partition coefficient 0.5, 1, 2, 5, 10 
𝐷 Diffusion coefficent for NO in polymers 
5.0 × 10-7, 2.0 × 10-6, 1.0 × 
10-5, 5.0 × 10-5 cm2·s-1 
OD_cat Outer diameter of the single lumen catheter 2.6 mm 
ID_cat Inner diameter of the single lumen catheter 2.0 mm 
OD_ele Outer diameter of the electrode 0.125 mm 
 
For response time estimation, a 2-D model of the cross-section of a single lumen 
catheter was implemented.  Similar 2-D equations for diffusion coupled by partition as 
described in Eqs (1) (4) (7) and (3) (5) (6) (9) are the governing equations for this  transport 
study, except the Neumann boundary condition of constant flux at the electrode surface 
was used instead of constant concentration.  In Domain III, an NO sink at 0.2 mm away 
from the catheter surface was purposely set to mimic the fact that NO is removed from the 
surface of the catheter very fast, either into the NOA by purging, or reacting with 
oxyhemoglobin when placed within the bloodstream in vivo.  For simulation of the 
distribution of NO around the outer surface of multi-lumen catheters, a similar model was 
used except the cross-section geometry was different.  The geometry and meshing of the 
model are shown in Figure 6.3, and the related parameters are shown in Table 6.1.  
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6.4 Results and Discussion 
6.4.1 Diffusion Studies of NO Through Polyurethanes 
 
Figure 6.4. Typical NO flux profile (JNO, black) and amount of permeated NO (QNO, red) vs. time 
for 368 µm E5-325 polyurethane at 25 °C in a diffusion experiment.  Red dotted line denotes the 
asymptote used for deriving the time lag. 
 
A typical NO flux and accumulative amount of permeated NO vs. time for NO 
diffusion through an E5-325 PU membrane is shown in Figure 6.4.  From the steady-state 
flux, together with membrane thickness, 𝐷𝐾 can be obtained according to Eq. 19.  After 
integration of the flux vs. time, an accumulated amount of permeated NO is obtained, 
which can be used to estimate time lag (τ) and calculate the diffusion coefficient.  Similar 
experiments were performed for the different polyurethane and silicone rubber films 
(structure description and selected physical properties of all the polymers under 
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investigation are listed in Table 6.1) at both 25 °C and 37 °C.  The measured coefficient 
and partition coefficients of NO in these polymers are summarized in Table 6.3. 
 
Table 6.3. Summary of diffusion coefficients and partition coefficients of NO in various polymers 
obtained in this study. 
Polymer 
𝐷298K 
/10-6 cm2 s-1 
𝐷310K 
/10-6 cm2 s-1 
K298K K310K 
Silicone 16±2 20±4 5±1 4±1 
E5-325 6±1 8.5±0.8 3.8±0.5 3.3±0.3 
PU SG80A 1.2±0.5 1.9±0.5 2.5±0.8 2.2±0.3 
Carbosil 20 80A 0.66±0.09 1.4±0.5 1.2±0.4 0.3±0.1 
Pellethane 80A 0.5±0.1 0.8±0.3 1.5±0.4 1.1±0.2 
Bionate 80A 0.3±0.1 0.7±0.1 0.7±0.2 0.6±0.1 
 
 
The diffusion coefficient of NO (𝐷 ) determined in the different polymers is 
negatively correlated to the density (ρ) of the polymer (see Figure 6.5).  This can be 
understood by the free volume theory,30 which suggests that diffusion in a polymer occurs 
by hopping between the holes of free volume, with the relationship: 
 
log𝐷 = 𝐴 −
𝐵
𝑓𝑣
 (20) 
where A and B are constants related to the size of the penetrants and hole size of the polymer 
matrix, respectively, and fv is the fraction of free volume.  Assuming similar densities of 
different polymer chains (occupied volumes) in this study, the specific density of a polymer 
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is negatively proportional to fv.  In fact, a direct relationship between fv and 𝐷 has been 
established experimentally by diffusion and positron annihilation lifetime experiments.31  
 
Figure 6.5. Specific density (ρ) of polymers vs. log of diffusion coefficient for NO (DNO).  
Correlation coefficient r = -0.75 for ρ vs. the log DNO.   
 
The PDMS polymer chain is flexible with a low barrier for rotation, which allows 
a large free volume and therefore fast diffusion for penetrants like NO.  Such a large free 
volume of PDMS is also indicated by the low glass transition temperature (Tg) of neat 
PDMS (-112 °C).32  This explains the fact that silicone rubber has the highest ?̅? for NO, 
and all the PUs containing PDMS segments examined in this study exhibit significantly 
higher diffusion coefficients for NO than similar PUs without the PDMS segments (e.g. 
E5-325 vs. Pellethane, Carbosil vs. Bionate). 
The polycarbonate chain (PHEC), while having a low Tg of -70 °C in the neat form, 
can form strong hydrogen bonds with urethane components in PUs.32  Such hydrogen 
bonding significantly decreases the free volume by closer packing and a reduction in chain 
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mobility, which is also indicated by the much higher Tg (-7 °C) of the PHEC segments in 
polycarbonate copolymers of PUs.32  This reduced free volume of PHEC chain in PUs 
explains the relatively slow diffusion of NO in Bionate and Carbosil. 
PU SG80A and Pellethane are both pure PUs with polyether as soft segments but 
exhibit quite different NO diffusion properties.  SG80A contains urethane segments from 
4,4′-methylene-bis(cyclohexyl isocyanate) (HMDI) and 1,4-butanediol (BDO), whereas 
Pellethane contains urethane segments from 4,4′-methylene-bis(phenyl isocyanate) (MDI) 
and BDO.25,27,33  As the aromatic MDI is more rigid than the aliphatic HMDI, PUs with 
segments from MDI have a larger barrier for chain rotation and therefore lower free volume.  
Therefore, PU SG80A exhibits a greater diffusion coefficient for NO than Pellethane.  
 
 
Figure 6.6. Cells of typical morphology (lamellae, spheres and cylinders) for block copolymers 
with phase separation. 
 
In addition to the chain flexibility and free volume, polymer morphology in block 
copolymers also significantly affect the diffusion of gas molecules.34  This is especially 
true for polyurethanes as they tend to micro-phase separate into different morphologies, 
including continuous phase with spheres, cylinders and lamellae.35  The exact morphology 
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depends on the miscibility of the blocks, stoichiometry of the blocks, and preparation 
conditions (including thermal history).36  In PUs with some PDMS within the copolymer 
chain, such as E5-325 and Carbosil, the PDMS segments undergo phase separation of 
nearly 100%.32,37  This allows the fraction of the PDMS phase to be simply represented by 
the stoichiometry.  Effective media theory has been proposed to model diffusion within 
polymer blends with different morphology, including spheres, cylinders and lamellae.38  
Such methods were first developed for solving issues of conductivity of composite 
materials, and the derived equations can be directly applied for diffusion by changing the 
conductivity into permeability.  The diffusion of gas in PUs can be modeled by considering 
compositions of cells with morphologies as shown in random orientation as shown in 
Figure 6.6. The relationship between volume fraction of PDMS phase and the predicted 
diffusion coefficient from different morphologies are plotted in Figure 6.7. 
E5-325 possesses segments of PDMS and MDI:BDO, and the PDMS content is as 
high as 66%.  This micro-morphology can be described as two phases comprising a 
continuous PDMS phase (66%) and discontinuous hard segment phase.  From Figure 6.7A, 
the point for E5-325 lies close to the predicted line for a cylinder of a hard phase in PDMS.  
However, a volume fraction of 66% is likely to be near the percolation threshold.39  
Predictions near the percolation threshold using this method often involves large error.40 
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Figure 6.7. Diffusion coefficient of NO (DNO) vs. volume fraction of PDMS (XA) in polymer based 
on different morphology for (A) Silicone-PU, and (B) Polycarbonate-Silicone-PU.  
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For Carbosil-20, the PDMS chains phase separate completely due to low 
compatibility with other chains.  From percolation theory, PDMS, with a volume fraction 
of 20%, is less likely to form a continuous phase.  Significant mixing of PHEC and the 
hard segment occurs, and only 10–15% of hard segment phase is separated (~4% of total 
volume).  To simplify the description using a two-phase model, the small amount of 
separated hard segment phase can be neglected.  Therefore, the morphology is described 
as continuous PHEC mixed phase with islands of PDMS.  From Figure 6.7B, it is likely 
that Carbosil-20 contains a lamellae structure of the PDMS component and the PHEC 
component.  
Diffusion coefficients and partition coefficients were obtained only at 25 °C and 
37 °C as these temperatures are most relevant for biomedical applications. As expected 
when the temperature increases, the diffusion coefficients of NO increase for all the 
polymers tested.  We did not attempt to derive an Arrhenius activation energy from the two 
temperature data points.  The activation energies would contain contributions from both 
the diffusant (NO) and the polymers and is less useful considering the complex 
composition and phase transitions of the different polymers at different temperatures.  
Errors in the diffusion experiments stem from many factors with major ones being 
the exact thickness of the membrane, the uncertainty arising from the response time of the 
NOA (2 s), and effectiveness of convection from stirring to NO source solution.  
In the experiment, asymmetry exists for the membrane as one side is contacting 
water (Domain I) while the other side is contacting gas (Domain III).  Such asymmetry, 
could potentially have an effect on the adsorption and desorption processes at the interfaces.  
In this experiment, the adsorption and desorption processes are assumed to occur very fast 
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for both the water/polymer interface and the gas/polymer interface.  If such an assumption 
is valid, the effect of asymmetry at the interface would be negligible.  The purpose for 
having gas on the other side instead of solution is to minimize the error by greatly 
decreasing the response time for the NO detection and to ensure that the downstream 
concentration is effectively zero at all times by quickly forcing the arriving NO into the 
detector.   
6.4.2 Effect of ?̅? and K on Response Time of NO Release 
Partition and diffusion affect NO transport in polymers and therefore can affect the 
NO release profile of some systems.  Particularly, the time it takes for NO release to reach 
steady-state, defined as the response time, is of importance as it can affect the 
performance/functionality of NO releasing device.  Catheters made from silicone and SG 
80A with electrochemical NO release system have been used to demonstrate such an effect.  
With the same geometry, catheters with different materials show very different diffusion 
profiles (see Figure 6.8).  For a pure PDMS catheter, the surface flux of NO reaches steady-
state within 5 min, whereas for a catheter made with PU SG80A, it takes more than 60 min 
to reach steady-state.  This is explained by the fact that the diffusion coefficient of NO in 
silicone is 13 times greater than that in PU SG 80A (see Table 6.3).  
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Figure 6.8. NO release profile for electrochemical NO releasing catheters made from silicone and 
PU SG80A determined by a nitric oxide analyzer. The catheters are 2.6 mm in o.d. and ~0.3 mm 
in wall thickness. 
 
 
Figure 6.9. Effect of diffusion and partition on NO release profile from electrochemical NO 
releasing catheters as determined by simulation. 
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The effect of ?̅? and K of NO in polymers on the NO release profile from a single 
lumen catheter was further investigated via finite element analysis using Comsol 
Multiphysics.  From the simulation result, the response time of NO release becomes faster 
as ?̅? and K increase (see Figure 6.9).  This result together with results of ?̅? and K in the 
diffusion study (Table 6.3) illustrates that to achieve a faster response time in 
electrochemical NO releasing catheters, silicone is the preferred material.  For a normal 
single lumen catheter with 0.3 mm wall thickness, the response time for silicone and E5 
will be ≤ 20 min.  The other polymers that have low ?̅? and K values for NO, although not 
ideal for electrochemical catheter application, could be used as release barriers to slow 
down the release of NO, or to prevent burst release.  For example, in drug delivery using 
nanoparticles, where prolonged release is often hard to achieve, calls for use of materials 
with low permeability as the outer barrier.41 
6.4.3 The Effect of ?̅? and K on NO Distribution on Multi-Lumen Catheters 
Another aspect of NO release is the distribution of NO on the surface of the devices.  
For example, application of electrochemical NO release in catheters requires multi-lumen 
catheters because one of the lumens needs to be sacrificed for the electrochemical NO 
generation system.  However, as most commercial multi-lumen catheters are not 
centrosymmetric, NO distribution around the outer surfaces of such catheters are likely to 
be asymmetric.  On the other hand, using a polymer with a high partition coefficient could 
serve as a reservoir for NO release, and that coupled with a high diffusion coefficient could 
promote a more symmetrical distribution of NO.  Both ?̅? and K, therefore, could impact 
the distribution of NO, besides the geometry of the device.   
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To study such asymmetry effects, a commercial dual lumen silicone catheter was 
simulated using ?̅? and K values obtained in this study.  Such a catheter has already been 
used in practice for conducting antithrombotic, antimicrobial studies as well as for 
preparing new NO release PO2 sensing catheters (see Chapter 3, 4, 5).
29,42  The local surface 
flux distribution for this catheter configuration is plotted in Figure 6.10a.  To quantify the 
worst case scenario of asymmetry, the ratio of the highest and the lowest local fluxes on 
the surface is used and is called maximum surface flux ratio (see Figure 6.10d).  The surface 
flux of NO increases as the time increases, and the maximum surface flux ratio decreases 
to <2 after 20 min in the absence of O2 (Figure 6.10).  With ambient O2 reacting with NO, 
the surface flux reaches a steady-state after 30 min, and the maximum surface flux ratio 
reaches 2.5 (Figure 6.10).  Such asymmetry was also probed experimentally by measuring 
the cumulative nitrite content (released NO reacts with O2 to form nitrite) at different sides 
of catheter in an agar gel into which e-chem NO releasing catheter was placed 
(experimental setup shown in Figure 6.11A).  As shown in Figure 6.11B, the results from 
the experiment agree well with the simulation.  
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Figure 6.10. Local surface flux of NO on a Cook 7 Fr dual lumen PDMS catheter at room 
temperature in N2 and in air. A) illustration of the polar angel for the dual lumen catheter; B) polar 
graph showing the local surface flux at different time in 0% and C) in 21% O2; D) Maximum 
surface flux ratio vs. time under 0 and 21% O2.  
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Figure 6.11. Experiment probing the distribution of NO by around a dual lumen catheter. A) 
experimental setup of catheter immobilization using agar; B) cumulative NO in the left and right 
domain of the catheter as measured by the agar immobilization experiment (dot) and simulation 
(line). 
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Figure 6.12. Effect of diffusion coefficient (𝐷 ) on distribution of NO on a catheter (same 
configuration of the Cook 7 Fr dual lumen catheter as shown in Figure 6.10) at 20 min.  Partition 
coefficient K = 2.5.  A) Polar graph of distribution of NO flux at catheter surface at 0% O2; B) 
maximum flux ratio vs. time at 0% O2; C) Polar graph of distribution of NO flux at catheter surface 
at 21% O2; D) maximum flux ratio vs. time at 21% O2. 
 
Using this geometry of the commercial dual-lumen catheter as an example, the 
effect of different values of ?̅?  and K on the NO distribution was further studied by 
simulation.  The lowest diffusion coefficient (5 × 10-7 cm2 s-1) shows the most asymmetric 
distribution of surface NO flux, with a maximum surface flux ratio of >10 (see Figure 6.12 
A).  Such a large asymmetry is partially a transient effect as the low diffusion coefficient 
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allows NO to permeate through one side of the catheter before a significant amount of NO 
appears at the other side.  With longer times (> 60 min), the asymmetry decreases (see 
Figure 6.12 B).  However, during all of the 60 min period used for our simulations, the 
symmetry is always significantly better with larger diffusion coefficients.  The same trend 
is true when reaction of NO with O2 is also considered, although the exact asymmetry is 
worse compared to under same conditions but without taking into account the reaction of 
NO with O2 (See Figure 6.12 C and D) 
The effect of partition coefficient on the distribution is more complex and is time-
dependent.  Without O2, the largest partition coefficient (K = 10; NO has favorable 
solubility in polymer phase) yields the lowest average flux of NO release at the 20 min (see 
Figure 6.13 A and B).  This is likely because with high partition coefficient, more NO 
needs to be dissolved in the polymer phase before being released.  A partition coefficient 
of 2 shows the best distribution at all time points.  With 21% O2, the average surface flux 
increases as K increases, but the trend for distribution changes with time.  K = 2 offers the 
best distribution within the first 18 min, and K = 5 shows a better distribution between 18 
and 36 min (see Figure 6.13 c and d).  After 36 min, a K = 10 exhibits the best distribution, 
reaching a steady rate of 3.6 after 70 min (Figure 6.13d). 
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Figure 6.13. Effect of partition coefficient (K) on distribution of NO for Cook 7 Fr dual lumen 
catheter at 20 min in 0% O2 and 21% O2.  Diffusion coefficient 𝐷 = 2×10-6 cm2 s-1.  A) Polar graph 
of distribution of NO flux at catheter surface without O2; B) maximum flux ratio vs time without 
O2; C) Polar graph of distribution of NO flux at catheter surface with 21 %; D) maximum flux ratio 
vs time with 21% O2. 
 
A more symmetric design has also been proposed (cross-section geometry shown 
in Figure 6.3C) and the distribution of NO for this design was also investigated by 
simulation methods.  The distribution of NO is indeed more symmetric for this more 
symmetric design; the maximum ratio of local surface fluxes falls below 2 after 20 min for 
𝐷 from 5.0 × 10-7 cm2 s-1 to 5.0 × 10-5 cm2 s-1 at a constant partition coefficient (see Figure 
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6.14A).  Similarly, the maximum ratio of local surface flux also falls below 2 after 20 min 
for K ranging from 0.5 to 10 at a constant diffusion coefficient (see Figure 6.14B). 
 
A)
 
B)
 
 
Figure 6.14. Effect of diffusion coefficient (𝐷) and partition coefficient (K) of NO in the polymer 
on the maximum ratio of local flux on an electrochemical NO releasing catheters with a more 
symmetric design as shown in Figure 6.3C.  A) varied 𝐷 with K = 2; B) varied K with 𝐷 = 2×10-6 
cm2 s-1. 
 
6.5 Conclusions 
Diffusion and partition coefficients for NO in silicone and different polyurethanes 
have been studied using a time lag method.  The diffusion coefficients for block co- and 
tripolymer PUs containing PDMS segments are explained by effective medium theory with 
different morphologies.  The effect of ?̅? and K on NO release response time as well as 
asymmetric NO distribution at the outermost surfaces of single and dual-lumen catheters 
have been examined both experimentally and by simulation.  Polymers with large ?̅? and K 
for NO exhibit faster response times.  Catheters made from polymers with larger ?̅? yield 
enhanced distribution of NO on the outer surface of the catheter.  A more symmetric design 
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for multi-lumen catheter has been proposed, and the NO distribution is indeed more 
symmetric for all the partition coefficients and diffusion coefficients modeled.  Overall, 
diffusion and partition coefficients of NO in polymers together with finite element analysis 
provide a powerful means in studying and designing novel NO releasing devices, especially 
new type of electrochemically generated NO catheters recently reported by our group.29,42 
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CHAPTER 7.  
 
 
ELECTROCHEMICAL GENERATION OF NO FOR POTENTIAL 
APPLICATION IN INHALED NO THERAPY 
 
7.1 Introduction 
As discussed in Chapter 1, nitric oxide (NO) is endogenously produced and plays 
key roles in several physiological processes, including inducing vasodilation, preventing 
platelet adhesion/activation and promoting wound healing and angiogenesis.1-6  Nitric 
oxide is also a potent antimicrobial agent released by macrophages and nasal epithelial 
cells to fight infection.7,8  Inspired by these functions, NO releasing materials have been 
developed and applied in different medical devices to improve their biocompatibility.9,10  
In addition, direct inhalation of nitric oxide (INO) has become a mainstay of intensive care 
for lung failure, since its first medical application 20 years ago.11  INO induces preferential 
pulmonary vasodilation and lowered pulmonary vascular resistance.12  As a result, INO has 
been approved for use in persistent pulmonary hypertension of newborn babies (PPHN) 
and has been demonstrated to improve oxygenation and reduce the need for the higher-risk 
extracorporeal membrane oxygenation (ECMO) therapy.13,14  INO is essential in 
neonatology, lung transplantation, and pulmonary hypertension.  Although currently only 
approved for treatment of PPHN, INO has shown beneficial effect on other illnesses 
including pneumonia,15 ARDS (acute respiratory distress syndrome),16 stroke,17 and 
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cardiopulmonary bypass.18  Recent studies have also reported the use of INO as an inhaled 
antiseptic agent in the treatment of cystic fibrosis19 and tuberculosis.20  Further, the anti-
inflammatory properties of INO have also been reported to modulate the immune response 
and promote survival in patients with malaria,21 a disease that affects 225–600 million 
worldwide each year.22  Long-term use of INO has been studied in some ambulatory 
patients with pulmonary hypertension,23 pulmonary fibrosis,24  and COPD (chronic 
obstruction pulmonary disorder).25  INO has also been demonstrated to provide 
neuroprotection and reduce brain damage.26 
At present, INO requires a gas cylinder of NO and a complex delivery device to 
regulate and monitor NO and is considered one of the most expensive drugs in neonatal 
medicine.27  The cost of implementing INO is $3000 per day per patient and the cost at the 
University of Michigan Hospital alone is $4.8M per year.28  Despite the expense of this 
system, the INO therapy is still considered cost effective in terms of decreasing the need 
for ECMO and essential to prevent death of some neonates.29  The cost mostly stems from 
the very expensive NO tank at ppm levels, which is a consumable and needs to be relatively 
fresh.  This is because NO undergoes disproportionation to form N2O and highly toxic NO2, 
especially at elevated pressure, limiting the use-life of a cylinder of NO >800 ppm in 
medical applications.30  On the other hand, the entire INO distribution system, especially 
the NO cylinder, is heavy and cumbersome.  Because of the high cost and the complexity 
of the system, INO is unavailable in many hospitals, and is not practical for outpatient 
usage.  An inexpensive yet portable device for INO is the key in making the INO available 
to more patients around the world, facilitating clinical trials of INO therapy on more 
diseases as described above, and ultimately making INO available for home use. 
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GeNO Inc. is developing a NO generation technique based on catalytic conversion 
of liquid NO2/N2O4 into NO.
31  However, using highly toxic NO2 as the starting material 
induces significant safety concerns.  Generation of NO from N2 and O2 via pulsed electrical 
discharges has also been demonstrated for INO application.32 However, NO generation is 
concomitant with formation of toxic NO2 and O3, which needs further scrubbing before 
use.   
In earlier work reported in this dissertation (see Chapters 3), generation of NO via 
electrochemical reduction of inexpensive nitrite ions was demonstrated and NO in 0-400 
ppb range at 0.2 L/min can be achieved by applying different potentials to the working 
electrode.33,34  Such an in situ electrochemical NO generation system is very attractive for 
INO as the NO can be produced on demand, and the NO levels produced can be easily 
regulated.  However, INO requires a much wider NO concentration range (up to 200 ppmv) 
at higher flow rates (from 1–5 L/min), which is 100–100,000 times higher than the original 
design that was described in our earlier work.  In this chapter, the generation of gas phase 
NO at concentrations relevant for INO therapy is explored using the new electrochemical 
NO generation system.  
 
7.2 Experimental Details 
7.2.1 Chemical and Materials 
Sodium nitrite (99.99%), HEPES acid (99.5%), HEPES sodium salt (99.5%), 
copper(II) sulfate pentahydrate (99.999%), and 1,4,7-trimethyl-1,4,7-triazacyclononane 
(Me3TACN) (97%) were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
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received.  All aqueous solutions were prepared with deionized water (18 M Ω cm-1) from 
a Milli-Q system (Millipore Corp., Billerica, MA).  Platinum (Pt) mesh (99.9%, 52 mesh, 
50 × 50 mm) was obtained from Sigma-Aldrich (St. Louis, MO), and a gold (Au) mesh 
electrode (99.99%, 52 mesh, 50 × 50 mm) was a product of Alfa Aesar (Ward Hill, MA).  
Teflon® PFA-coated platinum wires (0.125 mm OD) from A-M Systems (Sequim, WA) 
were used as lead wires for the mesh electrodes.  NO (45 ppm) and NO2 (20 ppm) standards 
were products from Cryogenic Gas Inc. (Detroit, MI). 
All the electrochemical experiments were performed on either a Gamry 600 
potentiostat or a CH Instrument 760 potentiostat.  The generation of NO was measured in 
real time via chemiluminescence by an NO analyzer from GE Analytics (Boulder, CO). 
7.2.2 Experimental Setup 
A homemade glass cell with port for a bubbler and gas outlet was filled with 80 mL 
solution of 7 mM CuMe3TACN, 1.0 M NaNO2 and 0.5 M HEPES buffer (pH 7.3).  Further 
electrochemical characterization of the Cu(II)Me3TACN complex is described in Appendix 
A.  The platinum mesh electrode and the Au mesh electrode were submerged in the solution 
and physically separated by a fritted glass bubbler to prevent short circuit. In the case where 
the potential on the working electrode needs to be determined, a reference electrode was 
added to the system.  The fritted glass bubbler was used to produce smaller bubbles so that 
the mass transfer of generated NO between aqueous phase and gas phase is greatly 
enhanced.  For long term experiments (electrolysis > 8 h), especially at higher flow rate 
(>1.0 L/min), the carrier gas (e.g., N2) was first passed through a 1.0 M NaCl solution to 
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take up some water (i.e., humidified) before entering the electrochemical cell, preventing 
the drying of the solution in the cell. 
7.2.3 Detection of N2O, NO2 and Aerosol 
N2O detection was carried out similar to a previously reported method based on gas 
phase IR spectroscopy.35  Briefly, the INO solution underwent bulk electrolysis at a 
constant current of 5 mA for 30 min.  The headspace of the cell was then sampled into the 
IR gas cell and quantification was based on integration of N2O feature peaks at 2235 and 
2212 cm-1 in the IR spectra using a calibration curve. 
NO2 was detected based on photolysis of NO2 to generate NO (see Figure 7.1 for 
the schematic).  The gas phase sample was passed through a photochemical reactor 
equipped with 350 nm UV lamp (Rayonet RPR-600, Branford, CT) in a U-shape glass tube 
before feeding into the nitric oxide analyzer (NOA).  The increased signal in the presence 
of the UV lamp being turned on was used for NO2 quantification.  NO2 at levels of 1–20 
ppmv (achieved by mixing different ratios of standard NO2 with N2 using a mass flow 
controller) was employed to calibrate the photolysis-chemiluminescence system to obtain 
NO2 conversion efficiency. 
Aerosol was detected by passing the gas into a septum sealed deoxygenated DI 
water for 5, 10 and 20 min, followed by removal of the dissolved NO by purging with high 
purity N2 for 10 min.  The nitrite in the solution was quantified using chemiluminescence.  
Briefly, an aliquot of the solution was injected to a cell containing 0.1 M H2SO4 and 5% 
KI solution that is connected to the nitric oxide analyzer. 
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Figure 7.1. Experimental setup for chemiluminescence detection of NO2. The sample is passed 
through a UV photochemical reactor and NO2 is converted to NO, which is subsequently detected 
by nitric oxide analyzer (NOA). 
 
7.3 Results and Discussion 
 
Figure 7.2. Schematic of bulk electrolysis cell for INO generation. WE: working electrode (Pt 
mesh); CE: counter electrode (Au mesh). The solution contains 7 mM CuMe3TACN, 1.0 M NaNO2 
and 0.5 M HEPES buffer (pH 7.3). 
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Figure 7.3. Modulation of NO concentration in gas phase by applying different constant currents. 
The bubbling gas is N2 at 1 L/min.  The solution contains 7 mM CuMe3TACN, 1.0 M NaNO2 and 
0.5 M HEPES buffer (pH 7.3). 
 
The electrochemical NO delivery system was accomplished in a glass cell for 
generation of gas phase NO for potential application in INO.  The schematic is shown in 
Figure 7.2.  In this two electrode system, a Pt mesh electrode was the working electrode 
and a Au mesh was the counter electrode.  By applying different constant currents between 
the electrodes, different concentrations of NO (from 0-200 ppm) can be generated in the 
gas phase, and the NO concentration is very stable (Figure 7.3).  The time for NO 
concentration to change from one level to another is less than 5 min, demonstrating a good 
temporal control of the system (Figure 7.3).  In this NO generation system, the constant 
current method was used to generate NO in contrast to the constant potential method 
introduced in the earlier catheter studies (see Chapter 3).34  There are several reasons 
behind this preference.  First, gas phase NO concentration is proportional to the NO flux 
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from the electrode surface at steady-state, which, in turn, is directly determined by the 
current on the working electrode.  Therefore, the constant current method provides a more 
stable NO concentration/generation rate and is less sensitive to fluctuations in temperature 
or solution composition.  Another advantage is that the constant current method consists 
of only two electrodes – a reference electrode is not necessary, making the electronics much 
simpler.   
 
Figure 7.4. Current vs. NO concentration in the gas phase at different flow rates and the 
corresponding faradaic efficiency.  The solution contains 7 mM CuMe3TACN, 1.0 M NaNO2 and 
0.5 M HEPES buffer (pH 7.3). 
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At different flow rates of the purge gas from 0.2 L/min to 3.0 L/min, NO 
concentrations of 10–150 ppm in N2 can be generated by applying different currents 
matching the flow rate (Figure 7.4).  Higher flow rates require higher current to yield the 
same NO concentration because of the dilution effect of the carrier gas.  Under a given 
flow rate, the NO concentration in the gas phase is proportional to the current applied (as 
shown in Figure 7.4), and the associated faradaic efficiency is relatively stable (fluctuation 
< 10%) for different currents.  This is because the system operates within 50% of the 
limiting current where no significant side reactions occur.  Also, the measured efficiencies 
are relatively high considering that both of the working and counter electrodes are in the 
same cell solution where reaction/consumption of product on the counter electrode is 
inevitable, and contributes to some decrease in efficiency.  
 
Figure 7.5. Effect of flow rate on NO concentration in the gas phase and current efficiencies at A) 
1 mA and B) 6 mA.  
 
The current efficiency increases as the bubbling/purge flow rate increases (Figure 
7.5).  This enhanced effect of bubbling/flow rate on current efficiency results from two 
processes.  Higher flow rate induces more efficient mass transfer, for both the catalyst to 
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get to the surface of the working electrode, as well as the substrate (nitrite) mixing with 
reduced catalyst very near the surface after the Cu(I)-ligand complex is formed.  Also, 
higher flow rate captures/purges more NO over a given time period, decreasing the 
concentration of NO in solution more effectively, preventing the cross reaction of product 
NO at the counter electrode, where oxidation to NO2 could occur.  
Nitric oxide generated from the electrochemical device is fresh at ambient pressure 
because the NO is produced in situ, avoiding production of N2O and toxic NO2 from 
disproportionation of NO, which remains a problem for NO in high pressure cylinders.  
The produced NO in N2 is pure with no NO2 or N2O detected in the gas phase, which is 
also indicated by the relatively high overall current efficiency.  No significant nitrite 
containing aerosol (<5 ppb) was detected.   
Based on the amount of nitrite (1.0 M) in the solution, the amount of NO (in moles) 
that can be produced from this electrochemical device is equivalent to more than 10 full 
cylinders of INO commercially available (D-size, 800 ppm, 2000 psig), yet the size of the 
device is less 20% of one cylinder.  Indeed, the bulk electrolysis of the one volume of nitrite 
solution (80 mL) yielded a stable NO concentration in the gas phase that would be 
equivalent to more than 2 cylinders of NO (See Figure 7.6). 
In addition, the NO generating solution is very stable under ambient conditions.  
During such storage in air for 60 days, the solution produced similar amount of NO at given 
current on different days (Figure 7.7).  Moreover, the same electrodes and electronics are 
also very stable and can be reused many times; the consumables are only the solution, 
which is very inexpensive compared to the current INO cylinder.   
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Figure 7.6. Electrochemical NO generation for INO at 3L/min from the same 80 mL solution at 
36 mA.  
 
 
Figure 7.7. NO generation from the same solution at 0.5 mA for 4 h each day.  The solution is 
stored at ambient conditions for up to 60 days.  
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It is desirable to demonstrate that instead of N2, air can also serve as a carrier gas.  
Using this system, ppm levels of NO in air can still be produced with essentially no NO2 
detected (<1 ppm) (Figure 7.8), although the concentration of NO is much lower (~80% 
reduction at 5 mA) than that if the carrier gas is N2 under the same conditions.  This is 
likely due to the reaction of NO and O2 with water to form nitrite, as well as the scavenging 
of Cu(I) by O2.  Since NO is generated at the surface of the electrode, its concentration is 
highest at the electrode surface.  Reaction between NO and O2 is second order with respect 
to NO both in the gas phase and in the solution phase, producing an increased reaction rate 
at higher NO concentrations.  The NO2 concentration from reaction of NO with air is shown 
in Figure 7.9 based on rate constant in the literature.36  In the gas phase, it takes 12 s to 
produce 1 ppm of NO2 from the reaction of 200 ppm NO and air.  In the solution phase, 
the product of NO oxidation is nitrite.  This explains why no significant NO2 (<1 ppm) is 
produced even when air was used as a carrier gas in the experiment.  This is likely because 
most of the reaction between NO and O2 occurs in the solution phase.  Overall, air can be 
used as carrier/bubbling gas for the electrochemical NO generation system, granting the 
system the potential to be transferred into a more portable device for use of INO at more 
sites, even at home.  In order to produce higher levels of INO for hospital use, using N2 as 
the purge gas and then combining this stream with a given flow of oxygen immediately 
before entering the patient would be the preferred arrangement.  
 
 171 
 
 
Figure 7.8. NO generation in gas phase using air as bubbling gas. Flow rate of air is 0.2 L/min. 
 
 
Figure 7.9. NO2 produced from reaction of NO at different concentration with air in the gas phase 
vs. duration of the reaction based on rate equation d[NO2]/dt=2 k [NO]2[O2], where k = 6.0 × 103 
M-2 s-1.  
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For a more compact design, silicone rubber bundles can also be employed as a gas 
exchange device directly inside the electrolyte solution (see Figure 7.10).  Again, as shown 
in Figure 7.11, NO levels over a clinically useful range can be generated in the gas phase, 
although the overall efficiency is slightly lower than the direct bubbling in the 
electrochemical cell.  Further, there is a longer lag period to change the gas phase levels to 
a new steady-state value when changing current applied.  This is likely because the rate is 
governed by the gas exchange at the solution/polymer and polymer/gas interfaces.   
  
 
 
Figure 7.10. Silicone rubber bundle design for gas exchange in electrolysis solution for INO 
generation. 
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Figure 7.11. NO generation from using silicone rubber bundle in the electrolysis solution for gas 
exchange. The bundles contain 8 silicone tubing (i.d. 0.51 mm, o.d. 0.94 mm, length 16 cm). Flow 
rate of N2 passing the bundles is 2 L/min. 
 
7.4 Conclusions 
In conclusion, using constant current method, relatively pure NO can be generated 
from electrochemical reduction of nitrite at the surface of a Pt mesh electrode.  The 
concentration of NO in the gas phase can range from 1–150 ppm at different flow rates, 
which is relevant for INO therapy and can potentially be a substitute for the NO tank 
currently used in the hospital.  The electrochemical INO system is robust and stable, and 
NO concentration in the gas phase can be easily tuned by applying different constant 
currents.  The system can also operate using air as carrier gas for NO, suggesting the 
possibility of developing a more portable INO device.  Such system can be readily adapted 
for oxygenator application, where a sweep gas of NO can potentially alleviate significant 
issues of clot formation in the use of oxygenators during open heart surgery and ECMO.  
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Finally, this robust NO generator can serve as a tool for fundamental 
biological/physiological studies requiring a given NO concentration in the gas phase, e.g. 
effect of NO on airway related diseases, both in vitro and in vivo. 
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CHAPTER 8.  
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
8.1 Conclusions 
As demonstrated within this dissertation, nitric oxide (NO), an endogenously 
produced small molecule, has many favorable physiological functions and can be used for 
improving the performance/biocompatibility of various medical devices from catheters to 
intervascular devices, as well as for certain treatments (e.g., chronic wounds, respiratory 
diseases etc.).  Controllable and inexpensive methods for release/delivery of NO would 
significantly facilitate the application of NO in various medical settings.  This thesis has 
focused on the development of electrochemical methods for modulated NO release from 
inexpensive inorganic nitrite salts.  
In Chapter 2, the NO generation was optimized from a Cu0 wire-based system in a 
catheter configuration.  Nitric oxide was generated by a pulse sequence containing anodic 
and cathodic pulses in sequence, and NO surface fluxes >1 × 10-10 mol min-1 cm-2 were 
shown to be readily generated from a single lumen catheter for more than 60 h.  Such 
electrochemical NO releasing catheters showed reduced clotting in vivo and prevented the 
formation of biofilms on their surfaces from S. aureus and E. coli in drip flow bioreactor 
experiments. 
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In Chapter 3, an alternate electrochemical NO generation method was developed 
using a copper(II)-ligand complex, CuTPMA, as a catalyst for electrochemical reduction 
of nitrite.  A constant reductive potential was applied on the working electrode to generate 
NO, and NO fluxes from (0–3.2) × 10-10 mol min-1cm-2 can be readily modulated by 
applying different potentials in a single lumen catheter setup.  Such a catheter was shown 
to release NO continuously for more than 8 days.  Such NO release was also applied in a 
dual-lumen catheter configuration and exhibited significant anti-clotting properties in vivo.  
It was further demonstrated that NO release for a short period of time (3 h) each day was 
sufficient to prevent the microbial biofilm formation on the catheter surface for over a 3-
day period. 
This electrochemical NO release system using CuTPMA as the electron transfer 
mediator/catalyst was further utilized for the development of a catheter-type 
electrochemical NO releasing PO2 sensor, as described in Chapter 4.  This PO2 sensor was 
based on the commercial dual lumen catheter.  One of the lumens was dedicated to 
electrochemical NO release as described in Chapter 3, and the other lumen was dedicated 
for PO2 sensing, similar to a Clark-type O2 sensor.
1  This newly-developed NO releasing 
PO2 sensing catheter provided much more accurate PO2 values when implanted in rabbit 
veins for 7 h and pig arteries for 21 h when compared with the control PO2 sensors without 
electrochemical NO release, which deviated negatively from the true value based on 
intermittent blood draws and in vitro measurements. 
In Chapter 5, the facile control of the NO release from the catheter surface was 
further utilized for fundamental dosage studies of NO on dispersal/killing of mature 
microbial biofilm.  NO release for 3 h in the physiologically relevant range showed 
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significant killing of mature P. aeruginosa biofilms.  Synergy between NO release and 
addition of the antibiotic gentamicin to the test media was also found.  This study not only 
demonstrated that electrochemical NO release provides  a robust tool for fundamental 
microbiological studies, but also suggests a viable means for controlling biofilm related 
infection in medical settings. 
In Chapter 6, transport of NO within and through polymers was studied to better 
understand/optimize the design of medical devices utilizing NO release.  The transport 
properties (diffusion coefficient and partition coefficient) of NO in different biomedical 
grade polymers were measured via diffusion experiments.  Such properties were then 
applied to finite element analysis (FEA) for simulating the NO release profile as well as its 
distribution in commercial dual lumen catheters.  The FEA method proves to be a useful 
tool in designing the optimal geometry of medical devices that exhibit NO release, 
especially utilizing the new electrochemical NO generating scheme described in Chapter 
3. 
In Chapter 7, the Cu(II)-ligand complex mediated electrochemical NO release was 
further adapted for potential application in inhaled NO (INO) therapy.  NO concentrations 
from 0–150 ppmv were produced in the gas phase using a constant current method with 
large area mesh electrodes, with no significant levels of NO2 or N2O detected.  This study 
further extends NO generation via the electrochemical method to a much higher 
concentration range, and demonstrates the possibility of using such a method for replacing 
the expensive tanks of NO employed for INO therapy in hospitals around the world.  
Preliminary screening and characterization of various Cu(II)-ligand complexes as 
catalysts for NO generation from nitrite are provided in Appendix A.  
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Overall, the electrochemical NO generation systems described in this thesis provide 
a versatile and robust means to create different NO-based medical devices.  One of the 
biggest advantages is the easy control of NO release levels.  The release of NO not only 
can be gated “on” and “off”, but the flux of NO release can also be modulated temporally 
by applying either different currents or different voltages to the working electrodes within 
the various devices. 
 
8.2 Future Directions 
8.2.1 Screening of More Cu(II)-Ligand Complexes for Better Catalysts 
Future directions involve both fundamental and applied studies.  For fundamental 
studies, more efficient and robust catalysts need to be developed for NO generation from 
nitrite.  Some modification of the existing catalysts can be potentially helpful in this regard.  
The structures of some potentially useful Cu(II)-ligand complexes are shown in Figure 8.1. 
Preliminary data have already already been collected with 3-[bis(2-
pyridylmethyl)amino]propionate (BMPA-Pr, Figure 8.1C n = 2).  This complex exhibits 
quasi-reversible electron transfer on Pt electrode (peak separation of ~90 mV) with E1/2 = 
-0.325 V vs. Ag/AgCl (3 M Cl-) and catalyzed reduction of nitrite with faradaic efficiency 
of NO > 30%.   
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Figure 8.1. Structures of new TACN derivatives and Cu(II) complexes that can be investigated in 
future work.  A) Cu(II)R3TACN(X)2, R = -Et, -iPr, -CH2CH2OH, or -iPrOH; B) asymmetric TACN 
derivatives: R’ = H (alcohol group) or carbonyl (carboxylate group); C) BMPA-carboxylate 
derivatives; n = 1–3; D) Cu(II)TAPMA(X)]. X = NO2-, H2O/HO-, CH3COO-, or Cl-, depending on 
experimental conditions. 
8.2.2 Exploration of Other Electrode Materials/Modification of the Electrodes 
Other inert and inexpensive electrode materials can be explored for use with the 
Cu(II)-ligand complex-based electrochemical NO generation system.  Preliminary studies 
suggest that carbon fibers can be used in a catheter setup for electrochemical NO generation.  
Stainless steel can also be used for NO generation, although the efficiency is lower, and 
some corrosion of the electrode occurs.  Further enhancement of the stability of these 
electrodes by anodization or by plating with inert metal (e.g., Au or Pt) on the surface 
should be considered. 
Another direction for future research would be to modify the surface of suitable 
electrodes with the Cu(II) catalysts, thereby converting a homogeneous catalysis system to 
a more robust/reusable heterogeneous one.  This modification can be achieved either by 
click chemistry (Figure 8.2A),2 or by electrooxidation of a catalyst containing aryl 
carboxylate groups on a graphitic surface (Figure 8.2B),3 or electroreduction of a 
diazonium salt,4 as well as formation of self-assembly monolayer of catalysts on a gold 
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electrode (Figure 8.2C).5  A catalyst with a large π system can also be noncovalent adsorbed 
onto a carbon surface by π- π interaction.6 
 
 
Figure 8.2. Various approaches to immobilize Cu(II)-ligand catalysts onto different electrode 
surfaces. A) Click chemistry to bind catalyst onto a graphitic surface; B) electro-grafting by 
coupling of an aryl radical to the graphitic surface via electrochemical oxidation of an aryl 
carboxylic acid; and C) attachment of catalyst to gold surface by a cystamine mediated self-
assembly monolayer. 
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In addition, Cu(II) complexes with a tridentate ligand could be potentially be bound 
to a pyridine or imidazole containing polymer, like poly(vinylpyridine) (PVPy) or 
poly(vinylimidazole) (PVI).  The structure of the resulting Cu(II)-containing polymers are 
shown in  
Figure 8.3.  Electron hopping between Cu sites can render the film conductive and 
such polymeric film can be cast onto the electrode surface for further catalytic studies.   
 
 
Figure 8.3. Attachment of Cu(II)-tridentate-ligand complexes to A) poly(vinylpyridine) and B) 
poly(vinylimidazole). 
 
8.2.3 Development of a Galvanic NO Release System or Photocatalytic System 
With a better understanding of the Cu(II) catalysts, the system could be adapted to 
a galvanic system where no external voltage source is required.  This can be achieved by 
coupling the reaction on the working electrode to another reaction on the counter electrode, 
that has its own redox potential that would create a galvanic cell that would discharge 
spontaneously to drive the reduction of nitrite.  
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On the other hand, a photocatalytic system where NO release from reduction of 
nitrite is driven by light will also be an interesting direction to pursue.  This can be achieved 
using a p-type semiconductor with band edge more negative than the formal potential for 
catalytic reduction of nitrite (e.g., GaAs7). 
8.2.4 Optimization in Catheters for Longer Term NO Release 
Longer term NO release in the catheter configuration can be optimized by using a 
more concentrated solution of nitrite and catalyst, ultimately for long-term animal studies.  
On the other hand, a method that involves changing the solution inside the catheter can 
also be explored.  Figure 8.4 illustrates a configuration of a catheter in which the inner 
filling solution can be easily changed or circulated, providing the potential to greatly 
prolong the NO release lifetime. 
 
Figure 8.4. Concept of circulating/changing the inner filling nitrite solution for electrochemical 
NO release. 
 
8.2.5 More Fundamental Antimicrobial Studies 
Utilizing the facile temporal control of the NO release, the effect of NO on biofilms 
at different stages of its formation should be possible.  For example, the dosage effect of 
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NO can be studied at the stage of initial attachment and the stage of colonization and growth 
of the bacteria (see Figure 1.1 in Chapter 1).   
In this dissertation, the pulsed/periodic release of NO on biofilm was only studied 
at 3 h/day for 3 days.  Other release frequencies should also be examined to determine the 
most efficient release frequency for preventing biofilm formation for a number of different 
microbes.   
Synergy between NO and antibiotics should be further investigated on other 
pathogenic bacteria strains, as well as using other common antibiotics (e.g., cephalosporin, 
commonly used to treat S. aureus biofilm) to test the generality of such synergy.  Ultimately, 
such synergy can be studied in vivo for both catheter-associated urinary tract infections 
(CAUTIs) and catheter-associated bloodstream infections (CABSIs), using the new 
electrochemical NO release catheter technology developed as part of this dissertation work.   
8.2.6 Improvement of Systems for INO 
For the INO project, a better design taking the whole system into account, including 
reactions on both the anode and cathode, to improve the overall efficiency should be further 
investigated.  The working and counter electrodes can be separated by an ion conductive 
membrane (e.g., Nafion), or by adding some anode depolarizer (electroactive species that 
can be oxidized on the counter electrode) to decrease the potential for NO oxidation or O2 
generation at the surface of the counter electrode.  Ideally, such an anode depolarizer can 
also serve as a proton source (e.g., N2H4 → N2 + 4H+ + 4e-) while being compatible with 
the cathode reaction.  
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The application of gas phase NO generated from the electrochemical system may 
be applicable for biological/physiological studies, e.g. airway related diseases, both in vitro 
and in vivo.  Development of a more portable device based on pumped air as the carrier gas 
should also be beneficial in expanding the use of INO to more places, and potentially for 
treatment of more diseases, including convenient home use.  The availability of suitable 
NO sensors that can detect the levels of the NO gas entering the patient is essential for such 
a system, and these sensors should provide signals that can servo-regulate the potential or 
current applied to the working electrode, thereby controlling the concentration of inhaled 
NO to a precise level. 
The research reported in this thesis only touched the surface in terms of 
fundamental and applied studies possible for the electrochemical NO generating/release 
concept.  Clearly, research in this area should be expanded on a number of fronts to realize 
the full potential of this relatively simple approach.  
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APPENDIX A. 
 
 
SUMMARY OF BEHAVIOR OF VARIOUS CU(II)-LIGAND COMPLEXES AS 
CATALYSTS FOR NO GENERATION VIA ELECTROCHEMICAL 
REDUCTION OF NITRITE  
 
A.1 Summary of the Electrochemical Properties Cu-Ligand Complexes 
In Chapter 3, CuTPMA was studied as a catalyst for NO generation by 
electrochemical reduction of nitrite ions.  In addition to this catalyst, other copper-ligand 
complexes have also been screened for similar NO generation from nitrite.  The ligands for 
these Cu(II) complexes can be categorized into three classes: 1) alkyl tripodal ligands, 
including tris(2-aminoethyl)amine (TREN) and its derivative tris[2-
(dimethylamino)ethyl]amine (Me6TREN); 2) pyridyl containing tripodal ligands, including  
tris(2-pyridylmethyl)amine (TPMA), 3-[bis(2-pyridylmethyl)amino]propionate (BMPA-
Pr), and  2-ethylthio-N,N-bis(pyridin-2-yl)methylethanamine (BMPA-SEt); and 3) 
tridentate cyclic compounds, including 1,4,7-triazacyclononane (TACN) and its N-methyl 
derivative, 1,4,7-trimethyl-1,4,7-triazacyclononane (Me3TACN).  The structures of these 
compounds are shown in Figure A.1. 
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Figure A.1. Structures of ligands that form strong Cu(II) complexes that have been studied in this 
work for electrochemical reduction of nitrite. 
 
Using cyclic voltammetry and bulk electrolysis in the presence of nitrite, these 
Cu(II)-ligand complexes were characterized for their formal potential, and their maximum 
NO production rate in the presence of 1 mM catalyst and 0.1 M nitrite.  The results are 
summarized in Table A.1.  These experiments were conducted using a 2 mm diameter Pt 
disk electrode with 1 mM Cu(II)-ligand complexes in 5 mL 0.1 M HEPES buffer solution 
(pH 7.3).  E1/2 is determined from the midpoint of cathodic and anodic peak potentials in 
CV at scan rate of 50 mV/s under N2.  Maximum NO generation rate was determined by a 
nitric oxide analyzer (NOA) during bulk electrolysis of the same solution in the presence 
of 0.1 M NaNO2 solution at potential more negative than the catalytic wave for reduction 
of nitrite.  Faradaic efficiency was calculated based on the ratio of amount of NO measured 
in the NOA measurement divided by Faraday’s constant to the charge passed based on the 
integration of the current.  
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Table A.1.  Summary of electrochemical properties of catalyst in aqueous solution.† 
 
† This data was collected in collaboration with Mr. Andrew Hunt from Dr. Lehnert Lab. 
* 1 mM CuIIL, 0.1 M nitrite, 0.1 M HEPES buffer (pH 7.3). 
 
A.2 Study of Cu(II)Me3TACN as Catalyst for NO Generation from Nitrite 
Among these catalysts, CuMe3TACN has the highest faradaic efficiency for NO 
generation.  The cyclic voltammogram (CV) of CuMe3TACN in the presence of different 
concentrations of nitrite is shown in Figure A.2.  The cathodic wave increases as the nitrite 
concentration increases, indicating the catalytic reaction likely through an EC’ mechanism, 
similar to that observed for CuTPMA.1  In the bulk electrolysis, NO at different fluxes can 
be generated by applying different voltages before the limiting current is reached (Figure 
A.3). 
 
Ligand
E1/2 /V
(vs. Ag/AgCl)
Max NO Rate *
/µmol s-1cm-2
Faradaic
Efficiency *
TREN - - < 0.1 %
Me6TREN -0.25 - < 0.1 %
TACN -0.24 - < 0.1 %
Me3TACN -0.24 5.7 -0.30V: 93%
BMPA-Pr -0.32 1.1 -0.30V: 32%
BMPA-SEt +0.25 - <0.1 %
TPMA -0.33 9.9 -0.32V: 28%
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Figure A.2. Cyclic voltamogram of 1 mM Cu(II)Me3TACN in 0.1 M HEPES buffer (pH 7.3) in 
the presence of different concentrations of NaNO2. 
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Figure A.3. NO release to gas phase from a 5 mL solution of 1 mM Cu(II)Me3TACN, 50 mM 
NaNO2, 0.1 M HEPES (pH 7.3), 0.1 M NaCl by different applied potential to a 2 mm diameter Pt 
working electrode.  Solution was continuously purged with nitrogen at flow rate of 50 mL/min.  
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The CuMe3TACN and nitrite solution was also studied in a single lumen catheter.  
The configuration of the catheter is the same as in Figures 3.6 and 3.7A.  The generated 
NO showed relatively stable flux for more than 16 h.  The average faradaic efficiency is 
70%.  At the end of the experiment, Cuo is deposited on the working electrode as evidenced 
by a stripping peak of Cuo in a fresh buffer solution (data not shown, also evidenced from 
the anodic peak ~-0.05 V in the CVs CuMe3TACN at 0 or low levels of nitrite; see Figure 
A.3).   
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Figure A.4. NO release from a single lumen catheter (i.d. 1.47 mm; o.d. 1.96 mm, 6 cm) using 0.5 
mM Cu(II)Me3TACN, 0.5 M NaNO2, 0.4 M HEPES and 0.16 M NaCl as inner solution.  Pt wire 
(o.d. 0.127 mm) was exposed for 2 cm and Ag/AgCl wire was exposed for 4 cm and coiled. Applied 
potential was -0.3 V vs Ag/AgCl wire.  
 
A.3 Side Reaction of CuMe3TACN—Disproportionation of Cu(I)  
The Cu0 deposited on the electrode surface is surmised through disproportionation 
of the electrochemically generated Cu(I)-ligand complex.  This was examined in more 
detail by conducting voltammetry on a 25 um microelectrode so that a higher scan rate can 
be achieved without significant complications from charging currents.  As shown in Figure 
A.5, the anodic peak at ~ -0.05 V is highly dependent on the scan rate.  The peak area 
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decreases as the scan rate increases.  This is because at higher scan rates, the homogeneous 
reaction (disproportionation) kinetics is slow compared to the scan rate, and most of the 
Cu(I) is not able to disproportionate before being re-oxidized back to the inert Cu(II) in the 
reverse scan.  
 
Figure A.5. Cyclic voltammogram of 2 mM CuMe3TACN in 0.1 M HEPES buffer on a 25 µm Pt 
microelectrode at different scan rates.  The peak on the anodic scan near -0.05 V correspond to the 
stripping of Cu0 on the electrode surface. 
 
A 2-D axial symmetry model for the 25 µm microelectrode was built to simulate 
the kinetics of the disproportionation reaction during the scans of CVs.  Bulter-Volmer 
kinetics was assumed as the boundary conditions on the electrode surface.2  The diffusion 
equation for Cu(I) was coupled with homogeneous disproportionation reaction d[Cu0]/dt = 
kdis [Cu(I)]2, where kdis is the second order rate constant for the disproportionation reaction.  
The simulated CV (without showing the anodic peak from stripping) at different scan rates 
is shown in Figure A.6.  The amount of Cu0 generated from simulation was compared with 
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that from the CV in the experiments using Faraday’s law (Q = nF) by integrating the anodic 
peak.  Simulation using a homogeneous rate constant of kdis = 1.2 × 102 M-1 s-1 yields a 
good fit with the experiment results at all scan rates (See Figure A.7).  
 
  
Figure A.6. Simulated CV of 2 mM CuMe3TACN on a 25 µm Pt microelectrode at different scan 
rate.  The reaction of disproportionation of Cu(I) was included. 
 
 
Figure A.7. Comparison of deposited Cu from experiment and simulation.  The stripping peak at 
~-0.05 V was used to calculate amount of deposited Cuo. 
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Such disproportionation was also found in the CuTACN complex, which has a 
similar structure with CuMe3TACN.  The disproportionation reaction for CuTACN is 
much faster than that for CuMe3TACN, with k
dis =2.50 × 103 M-1 s-1.  This indicates that 
Cu(I)TACN is less stable than Cu(I)Me3TACN, which explains why no nitrite reduction 
was observed for CuTACN.  Structurally, the methyl groups in CuMe3TACN provide more 
steric and therefore slow down the disproportionation reaction, which needs two Cu(I) 
complex to approach each other in close proximity.  
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